ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 300 mg concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 300 mg mirikizumab in 15 mL solution (20 mg/mL).

After dilution (see section 6.6), the final concentration is approximately 1.1 mg/mL to approximately 4.6 mg/mL for the treatment of ulcerative colitis and approximately 3.6 mg/mL to approximately 9 mg/mL for the treatment of Crohn's disease.

Mirikizumab is a humanised monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

Excipients with known effect

Each 15 mL vial contains approximately 60 mg sodium.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Concentrate for solution for infusion (sterile concentrate)

The concentrate is a clear and colourless to slightly yellow solution with a pH of approximately 5.5 and an osmolarity of approximately 300 mOsm/L.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Ulcerative colitis

Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Crohn's disease

Omvoh is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

4.2 Posology and method of administration

This medicinal product is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of ulcerative colitis or Crohn' disease. Omvoh 300 mg concentrate for solution for infusion should only be used for the induction dose.

Posology

Ulcerative colitis

The recommended mirikizumab dose regimen has 2 parts.

Induction dose

The induction dose is 300 mg by intravenous infusion for at least 30 minutes at weeks 0, 4 and 8.

Maintenance dose

The maintenance dose is 200 mg (i.e. two 100 mg pre-filled syringes or two 100 mg pre-filled pens) by subcutaneous injection every 4 weeks after completion of induction dosing.

For the posology of the subcutaneous dosing regimen, see section 4.2 of the Summary of Product Characteristics for Omvoh 100 mg solution for injection in pre-filled syringe and Omvoh 100 mg solution for injection in pre-filled pen.

Patients should be evaluated after the 12-week induction dosing and if there is adequate therapeutic response, transition to maintenance dosing. For patients who do not achieve adequate therapeutic benefit at week 12 of induction dosing, mirikizumab 300 mg by intravenous infusion may be continued at weeks 12, 16 and 20 (extended induction therapy). If therapeutic benefit is achieved with the additional intravenous therapy, patients may initiate mirikizumab subcutaneous maintenance dosing (200 mg) every 4 weeks, starting at week 24. Mirikizumab should be discontinued in patients who do not show evidence of therapeutic benefit to extended induction therapy by week 24.

Patients with loss of therapeutic response during maintenance treatment may receive 300 mg mirikizumab by intravenous infusion every 4 weeks, for a total of 3 doses (re-induction). If clinical benefit is achieved from this additional intravenous therapy, patients may resume mirikizumab subcutaneous dosing every 4 weeks. The efficacy and safety of repeated re-induction therapy have not been evaluated.

Crohn's disease

The recommended mirikizumab dose regimen has 2 parts.

Induction dose

The induction dose is 900 mg (3 vials of 300 mg each) by intravenous infusion for at least 90 minutes at weeks 0, 4 and 8.

Maintenance dose

The maintenance dose is 300 mg (i.e. one pre-filled syringe or pre-filled pen of 100 mg and one pre-filled syringe or pre-filled pen of 200 mg) by subcutaneous injection every 4 weeks after completion of induction dosing.

The injections may be administered in any order.

The 200 mg pre-filled syringe and 200 mg pre-filled pen are only for the treatment of Crohn's disease.

For the posology of the subcutaneous dosing regimen, see section 4.2 of the Summary of Product Characteristics for Omvoh solutions for injection in pre-filled syringe and pre-filled pen. Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by week 24.

Special populations

<u>Elderly</u>

No dose adjustment is required (see section 5.2). There is limited information in subjects aged \geq 75 years.

Renal or hepatic impairment

Omvoh has not been studied in these patient populations. These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary (see section 5.2).

Paediatric population

The safety and efficacy of Omvoh in children and adolescents aged 2 to less than 18 years have not yet been established. No data are available.

There is no relevant use of Omvoh in children below 2 years for the indication of ulcerative colitis or Crohn's disease.

Method of administration

Omvoh 300 mg concentrate for solution for infusion is for intravenous use only. Each vial is for single use only.

For instructions on dilution of the medicinal product before administration, see section 6.6.

Administration of the diluted solution

- The intravenous administration set (infusion line) should be connected to the prepared intravenous bag and the line should be primed.
 - For ulcerative colitis the infusion should be administered for at least 30 minutes.
 - For Crohn's disease the infusion should be administered for at least 90 minutes.
- At the end of the infusion, to ensure a full dose is administered, the infusion line should be flushed with sodium chloride 9 mg/mL (0.9 %) solution or 5 % glucose solution for injection. The flush should be administered at the same rate as used for Omvoh administration. The time required to flush Omvoh solution from the infusion line is in addition to the minimum 30 minutes (ulcerative colitis) or 90 minutes (Crohn's disease) infusion time.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Clinically important active infections (active tuberculosis).

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity reactions

In clinical studies, hypersensitivity reactions have been reported. Most were mild or moderate, severe reactions were uncommon (see section 4.8). If a serious hypersensitivity reaction, including

anaphylaxis, occurs, mirikizumab must be discontinued immediately and appropriate therapy must be initiated.

Infections

Mirikizumab may increase the risk of severe infection (see section 4.8). Treatment with mirikizumab should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated (see section 4.3). The risks and benefits of treatment should be considered prior to initiating use of mirikizumab in patients with a chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops, discontinuation of mirikizumab should be considered until the infection resolves.

Pre-treatment evaluation for tuberculosis

Prior to initiating treatment, patients should be evaluated for tuberculosis (TB) infection. Patients receiving mirikizumab should be monitored for signs and symptoms of active TB during and after treatment. Anti-TB therapy should be considered prior to initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Hepatic enzyme elevations

Cases of drug-induced liver injury (including one case meeting Hy's Law criteria) occurred in patients receiving mirikizumab in clinical trials. Liver enzymes and bilirubin should be evaluated at baseline and monthly during induction (including extended induction period, if applicable). Thereafter, liver enzymes and bilirubin should be monitored (every 1 - 4 months) according to standard practice for patient management and as clinically indicated. If increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) are observed and drug-induced liver injury is suspected, mirikizumab must be discontinued until this diagnosis is excluded.

Immunisations

Prior to initiating therapy with mirikizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. Avoid use of live vaccines in patients treated with mirikizumab. No data are available on the response to live or non-live vaccines.

Excipients with known effect

<u>Sodium</u>

Ulcerative colitis

This medicinal product contains 60 mg sodium per 300 mg dose, equivalent to 3 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

If prepared with sodium chloride 9 mg/mL (0.9 %) solution for injection, the amount of sodium contributed by the sodium chloride diluent will range from 177 mg (for a 50 mL bag) to 885 mg (for a 250 mL bag), equivalent to 9-44 % of the WHO recommended maximum daily intake. This is in addition to the amount contributed by the medicinal product.

Crohn's disease

This medicinal product contains 180 mg sodium per 900 mg dose, equivalent to 9 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

If prepared with sodium chloride 9 mg/mL (0.9 %) solution for injection, the amount of sodium contributed by the sodium chloride diluent will range from 195 mg (for a 100 mL bag) to 726 mg (for a 250 mL bag), equivalent to 10-36 % of the WHO recommended maximum daily intake. This is in addition to the amount contributed by the medicinal product.

<u>Polysorbate</u>

This medicinal product contains 0.5 mg/mL of polysorbate 80 in each vial which is equivalent to 7.5 mg for the induction dose to treat ulcerative colitis and equivalent to 22.5 mg for the induction dose to treat Crohn's disease. Polysorbates may cause allergic reactions.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

In clinical studies, concomitant use of corticosteroids or oral immunomodulators did not influence the safety of mirikizumab.

Population pharmacokinetic data analyses indicated that the clearance of mirikizumab was not impacted by concomitant administration of 5-ASAs (5-aminosalicylic acid), corticosteroids or oral immunomodulators (azathioprine, 6-mercaptopurine, thioguanine, and methotrexate).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment.

Pregnancy

There is a limited amount of data from the use of mirikizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Omvoh during pregnancy.

Breast-feeding

It is unknown whether mirikizumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Omvoh therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

The effect of mirikizumab on human fertility has not been evaluated (see section 5.3).

4.7 Effects on ability to drive and use machines

Omvoh has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions are upper respiratory tract infections (9.8 %, most frequently nasopharyngitis), headache (3.2 %), rash (1.3 %) and injection site reactions (10.8 %, maintenance period).

Tabulated list of adverse reactions

Adverse reactions from clinical studies (Table 1) are listed by MedDRA system organ class. The frequency category for each reaction is based on the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to < 1/10); uncommon ($\geq 1/1000$ to < 1/100); rare ($\geq 1/10000$ to < 1/1000); very rare (< 1/10000).

| MedDRA System organ class | Frequency | Adverse reaction |
|--------------------------------|-------------|---|
| Infections and infestations | Common | Upper respiratory tract infections ^a |
| | Uncommon | Herpes zoster |
| Immune system disorders | Uncommon | Infusion-related hypersensitivity reactions |
| Musculoskeletal and Connective | Common | Arthralgia |
| Tissue Disorders | | |
| Nervous system disorders | Common | Headache |
| Skin and subcutaneous tissue | Common | Rash ^b |
| disorders | | |
| General disorders and | Very common | Injection site reactions ^c |
| administration site conditions | Uncommon | Infusion site reactions ^d |
| Investigations | Uncommon | Alanine aminotransferase increased |
| | Uncommon | Aspartate aminotransferase increased |

Table 1: Adverse reactions

^a Includes: acute sinusitis, COVID-19, nasopharyngitis, oropharyngeal discomfort, oropharyngeal pain, pharyngitis, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, and viral upper respiratory tract infection.

^b Includes: rash, rash macular, rash maculo-papular, and rash papular and rash pruritic.

- ^c Reported during mirikizumab maintenance therapy where mirikizumab treatment is administered as subcutaneous injection.
- ^{*d*} Reported during mirikizumab induction therapy where mirikizumab treatment is administered as intravenous infusion.

Description of selected adverse reactions

Infusion-related hypersensitivity reactions (induction therapy)

Infusion-related hypersensitivity reactions were reported in 0.4 % of mirikizumab-treated patients. All infusion-related hypersensitivity reactions were reported as non-serious.

Injection site reactions (maintenance therapy)

Injection site reactions were reported in 10.8 % of mirikizumab-treated patients. The most frequent reactions were injection site pain, injection site reaction and injection site erythema. These symptoms were reported as non-serious, mild and transient in nature.

The results described above were obtained with the original formulation of Omvoh. In a double blind, 2-arm, randomised, single-dose, parallel design study in 60 healthy subjects comparing 200 mg mirikizumab (2 injections of 100 mg in a pre-filled syringe) of the original formulation with the revised formulation statistically significantly lower VAS pain scores were obtained with the revised (12.6) vs. the original formulation (26.1) 1 minute after injection.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increased In the first 12 weeks, ALT increased was reported in 0.6 % mirikizumab-treated patients. AST increased was reported by 0.4 % mirikizumab-treated patients. All adverse reactions were reported as mild to moderate in severity and non-serious.

Overall mirikizumab treatment periods in the ulcerative colitis and Crohn's disease clinical development program (including the placebo-controlled and open label induction and maintenance periods), there have been elevations of ALT to $\geq 3 x$ upper limit of normal (ULN) (2.3 %), $\geq 5 x$ ULN (0.7 %) and $\geq 10 x$ ULN (0.2 %) and AST to $\geq 3 x$ ULN (2.2 %), $\geq 5 x$ ULN (0.8 %) and $\geq 10 x$ ULN (0.1 %) in patients receiving mirikizumab (see section 4.4). These elevations have been noted with and without concomitant elevations in total bilirubin.

Immunogenicity

In the ulcerative colitis studies, up to 23 % of mirikizumab-treated patients with 12 months of treatment developed anti-drug antibodies, most of which were of low titer and tested positive for neutralising activity. Higher antibody titers in approximately 2 % of subjects treated with mirikizumab were associated with lower serum mirikizumab concentrations and reduced clinical response.

In the Crohn's disease study, 12.7% of mirikizumab-treated patients with 12 months of treatment developed anti-drug antibodies, most of which were of low titer and tested positive for neutralising activity. There was no identified clinically significant effect of anti-drug antibodies on pharmacokinetics or effectiveness of mirikizumab.

No association was found between anti-mirikizumab antibodies and hypersensitivity or injectionrelated events in either the ulcerative colitis or the Crohn's disease studies.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in <u>Appendix V</u>.

4.9 Overdose

Mirikizumab doses up to 2 400 mg intravenously and up to 500 mg subcutaneously have been administered in clinical trials without dose-limiting toxicity. In the event of overdose, the patient must be monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment must be started immediately.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC24

Mechanism of action

Mirikizumab is a humanised IgG4 monoclonal, anti-interleukin-23 (anti-IL-23) antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.

IL-23, a regulatory cytokine, affects the differentiation, expansion, and survival of T cell subsets, (e.g., Th17 cells and Tc17 cells) and innate immune cell subsets, which represent sources of effector

cytokines, including IL-17A, IL-17F and IL-22 that drive inflammatory disease. In humans, selective blockade of IL-23 was shown to normalise production of these cytokines.

Pharmacodynamic effects

Inflammatory biomarkers were measured in the phase 3 ulcerative colitis and Crohn's disease studies. Mirikizumab administered intravenously every 4 weeks during induction dosing significantly reduced levels of fecal calprotectin and C-reactive protein from baseline to week 12. Also, mirikizumab administered subcutaneously every 4 weeks during maintenance dosing sustained significantly reduced levels of fecal calprotectin and C-reactive protein up to 52 weeks.

Clinical efficacy and safety

Ulcerative colitis

The efficacy and safety of mirikizumab was evaluated in adult patients with moderately to severely active ulcerative colitis in two randomised, double-blind, placebo-controlled, multicentre studies. Enrolled patients had a confirmed diagnosis of ulcerative colitis for at least 3 months and moderately to severely active disease, defined as a modified Mayo score of 4 to 9, including a Mayo endoscopy subscore ≥ 2 . Patients had to have failed (defined as loss of response, inadequate response or intolerance) corticosteroids or immunomodulators (6-mercaptopurine, azathioprine) or at least one biologic (a TNF α antagonist and/or vedolizumab) or tofacitinib.

LUCENT-1 was an intravenous induction study with treatment of up to 12 weeks, followed by a 40 week subcutaneous randomised withdrawal maintenance study (LUCENT-2), representing at least 52 weeks of therapy. Mean age was 42.5 years. 7.8 % of patients were \geq 65 of age and 1.0 % of patients \geq 75 of age. 59.8 % were men; 40.2 % were women. 53.2 % had severely active disease with a modified Mayo score 7 to 9.

Efficacy results presented for LUCENT-1 and LUCENT-2 were based on central reading of endoscopies and histology.

LUCENT-1

LUCENT-1 included 1 162 patients in the primary efficacy population. Patients were randomised to receive a dose of 300 mg mirikizumab via intravenous infusion or placebo, at week 0, week 4 and week 8 with a 3:1 treatment allocation ratio. The primary endpoint for the induction study was the proportion of subjects in clinical remission [modified Mayo score (MMS) defined as: Stool frequency (SF) subscore = 0 or 1 with $a \ge 1$ -point decrease from baseline, and rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)] at week 12.

Patients in these studies may have received other concomitant therapies including aminosalicylates (74.3 %), immunomodulatory agents (24.1 % such as azathioprine, 6-mercaptopurine or methotrexate), and oral corticosteroids (39.9 %; prednisone daily dose up to 20 mg or equivalent) at a stable dose prior to and during the induction period. Per protocol oral corticosteroids were tapered after induction.

Of the primary efficacy population, 57.1 % were biologic-naive and tofacitinib-naive. 41.2 % of patients had failed a biologic or tofacitinib. 36.3 % of the patients had failed at least 1 prior anti-TNF therapy, 18.8 % had failed vedolizumab and 3.4 % of patients had failed tofacitinib. 20.1 % had failed more than one biologic or tofacitinib. An additional 1.7 % had previously received but had not failed a biologic or tofacitinib.

In LUCENT-1 a significantly greater proportion of patients were in clinical remission in the mirikizumab treated group compared to placebo at week 12 (Table 2). As early as week 2, mirikizumab-treated patients achieved a greater reduction in RB subscores and decreases in SF subscores.

Table 2: Summary of key efficacy outcomes in LUCENT-1 (week 12 unless indicated otherwise)

| | Pla n = | Placebo Miriki n = 294 n = | | zumab IV = 868 | Treatment |
|---|------------|-------------------------------|---------|-------------------|---|
| | n | % | n | % | and 99.875 % CI |
| Clinical remission* ¹ | 39 | 13.3 % | 210 | 24.2 % | 11.1 % (3.2 %, 19.1 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 27/171 | 15.8 % | 152/492 | 30.9 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/118 | 8.5 % | 55/361 | 15.2 % | |
| Alternate clinical remission* ² | 43 | 14.6 % | 222 | 25.6 % | 11.1 % (3.0 %, 19.3 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 31/171 | 18.1 % | 160/492 | 32.5 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/118 | 8.5 % | 59/361 | 16.3 % | |
| Clinical response* ³ | 124 | 42.2 % | 551 | 63.5 % | 21.4 % (10.8 %, 32.0 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 86/171 | 50.3 % | 345/492 | 70.1 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 35/118 | 29.7 % | 197/361 | 54.6 % | |
| Endoscopic improvement* ⁴ | 62 | 21.1 % | 315 | 36.3 % | 15.4 % (6.3 %, 24.5 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 48/171 | 28.1 % | 226/492 | 45.9 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 12/118 | 10.2 % | 85/361 | 23.5 % | |
| Symptomatic remission (week 4)* ⁵ | 38 | 12.9 % | 189 | 21.8 % | 9.2 % (1.4 %, 16.9 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 26/171 | 15.2 % | 120/492 | 24.4 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/118 | 8.5 % | 67/361 | 18.6 % | |
| Symptomatic remission* ⁵ | 82 | 27.9 % | 395 | 45.5 % | 17.5 % (7.5 %, 27.6 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 57/171 | 33.3 % | 248/492 | 50.4 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 22/118 | 18.6 % | 139/361 | 38.5 % | |
| Histo-endoscopic mucosal improvement ^{*6} | 41 | 13.9 % | 235 | 27.1 % | 13.4 % (5.5 %, 21.4 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 32/171 | 18.7 % | 176/492 | 35.8 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 8/118 | 6.8 % | 56/361 | 15.5 % | |
| | 1 | | | | • |

| Pla n : | acebo = 294 | Miriki n = | zumab IV = 868 | Treatment |
|------------|-------------------|---------------|-------------------|-----------------|
| LS mean | Standard error | LS mean | Standard error | and 99.875 % CI |

| Bowel urgency severity* ⁷ | -1.63 | 0.141 | -2.59 | 0.083 | -0.95 (-1.47, -0.44)° |
|---|-------|-------|-------|-------|--------------------------|
| Patients who were biologic and JAK-inhibitor naïve ^a | -2.08 | 0.174 | -2.72 | 0.101 | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | -0.95 | 0.227 | -2.46 | 0.126 | |

Abbreviations: CI = confidence interval; IV = intravenous; LS = least square

- *¹ Clinical remission is based on the modified Mayo score (MMS) and is defined as: Stool frequency (SF) subscore = 0 or 1 with $a \ge 1$ -point decrease from baseline, and Rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)
- *² Alternate clinical remission is based on the modified Mayo score (MMS) and is defined as: Stool frequency (SF) subscore = 0 or 1, and Rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)
- *³ Clinical response based on the MMS and is defined as: A decrease in the MMS of ≥ 2 points and ≥ 30 % decrease from baseline, and a decrease of ≥ 1 point in the RB subscore from baseline or a RB score of 0 or 1
- *⁴ Endoscopic improvement defined as: ES = 0 or 1 (excluding friability)
- *⁵ Symptomatic remission defined as: SF = 0, or SF = 1 with $a \ge 1$ -point decrease from baseline, and RB = 0
- *⁶ Histo-endoscopic mucosal improvement defined as achieving both: 1. Histologic improvement, defined using Geboes scoring system with neutrophil infiltration in < 5 % of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue. 2. Endoscopic improvement, defined as ES = 0 or 1 (excluding friability).
- *7 Change from baseline in the Urgency Numeric Rating Scale score
- *a)* An additional 5 patients on placebo and 15 patients on mirikizumab where previously exposed to but did not fail a biologic or JAK-inhibitor.
- b) Loss of response, inadequate response or intolerance.
- c) p < 0.001
- *d) Mirikizumab results in the subgroup of patients who failed more than one biologic or JAK-inhibitor were consistent with results in the overall population.*

LUCENT-2

LUCENT-2 evaluated 544 patients out of the 551 patients who achieved clinical response with mirikizumab in LUCENT-1 at week 12 (see Table 2). Patients were re-randomised in a 2:1 treatment allocation ratio to receive a subcutaneous maintenance regimen of 200 mg mirikizumab or placebo every 4 weeks for 40 weeks (which is 52 weeks from initiation of the induction dose). The primary endpoint for the maintenance study was the proportion of subjects in clinical remission (same definition as in LUCENT-1) at week 40. Corticosteroid tapering was required upon entrance into LUCENT-2 for patients who were receiving corticosteroids during LUCENT-1. Significantly greater proportions of patients were in clinical remission in the mirikizumab-treated group compared to the placebo group at week 40 (see Table 3).

Table 3: Summary of key efficacy measures in LUCENT-2 (week 40; 52 weeks from initiation of the induction dose)

| | Placebo n = 179 | | Mirikiz n = | umab SC = 365 | Treatment difference and 95 % CI |
|---|--------------------|--------|----------------|------------------|---|
| | n | % | n | % | |
| Clinical remission*1 | 45 | 25.1 % | 182 | 49.9 % | 23.2 % (15.2 %, 31.2 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 35/114 | 30.7 % | 118/229 | 51.5 % | |

| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/64 | 15.6 % | 59/128 | 46.1 % | |
|---|--------------------|----------|---------------------------|----------|---|
| Alternate clinical remission* ² | 47 | 26.3 % | 189 | 51.8 % | 24.1 % (16.0 %, 32.2 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 37/114 | 32.5 % | 124/229 | 54.1 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/64 | 15.6 % | 60/128 | 46.9 % | |
| Maintenance of clinical remission through week 40* ³ | 24/65 | 36.9 % | 91/143 | 63.6 % | 24.8 % (10.4 %, 39.2 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 22/47 | 46.8 % | 65/104 | 62.5 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 2/18 | 11.1 % | 24/36 | 66.7 % | |
| Corticosteroid-free remission ^{*4} | 39 | 21.8 % | 164 | 44.9 % | 21.3 % (13.5 %, 29.1 %)° |
| Patients who were biologic and JAK-inhibitor naïve ^a | 30/114 | 26.3 % | 107/229 | 46.7 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 9/64 | 14.1 % | 52/128 | 40.6 % | |
| Endoscopic improvement* ⁵ | 52 | 29.1 % | 214 | 58.6 % | 28.5 % (20.2 %, 36.8 %)° |
| Patients who were biologic and JAK-inhibitor naïve ^a | 39/114 | 34.2 % | 143/229 | 62.4 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 13/64 | 20.3 % | 65/128 | 50.8 % | |
| Histo-endoscopic mucosal remission* ⁶ | 39 | 21.8 % | 158 | 43.3 % | 19.9 % (12.1 %, 27.6 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 30/114 | 26.3 % | 108/229 | 47.2 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 9/64 | 14.1 % | 46/128 | 35.9 % | |
| Bowel urgency remission*7 | 43/172 | 25.0 % | 144/336 | 42.9 % | 18.1 % (9.8 %, 26.4 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 31/108 | 28.7 % | 96/206 | 46.6 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 12/63 | 19.0 % | 43/122 | 35.2 % | |
| | | | | | |
| | Placebo n = 179 | | Mirikizumab SC n = 365 | | Treatment difference and 95 % CI |
| | LS | Standard | LS | Standard | |
| | mean | error | mean | error | |
| | | | | | |
| Bowel urgency severity ^{*8} | -2.74 | 0.202 | -3.80 | 0.139 | -1.06 (-1.51, -0.61) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | -2.69 | 0.233 | -3.82 | 0.153 | |
| Patients who failed ^b at least | -2 66 | 0.346 | -3.60 | 0.228 | |

Abbreviations: CI = confidence interval; SC = subcutaneous; LS = least square

*^{1, 2} See footnotes on Table 2

- *³ The proportion of patients who were in clinical remission at week 40 among patients in clinical remission at week 12, with clinical remission defined as: Stool frequency (SF) subscore = 0 or SF = 1 with $a \ge 1$ -point decrease from induction baseline, and Rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)
- *⁴ Corticosteroid-free remission without surgery, defined as: Clinical remission at week 40, and Symptomatic remission at week 28, and no corticosteroid use for ≥ 12 weeks prior to week 40
- *⁵ Endoscopic improvement defined as: ES = 0 or 1 (excluding friability)
- *6 Histo-endoscopic mucosal remission, defined as achieving both: 1. Histologic remission, defined as Geboes subscores of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration) and 2. Mayo endoscopic score 0 or 1 (excluding friability)
- *⁷ Numeric Rating Scale (NRS) 0 or 1 in patients with urgency NRS \geq 3 at baseline in LUCENT-1
- *⁸ Change from baseline in the Urgency NRS score
- *a)* An additional 1 patient on placebo and 8 patients on mirikizumab where previously exposed to but did not fail a biologic or JAK-inhibitor.
- b) Loss of response, inadequate response or intolerance.
- c) p < 0.001
- *d) Mirikizumab results in the subgroup of patients who failed more than one biologic or JAK-inhibitor were consistent with results in the overall population.*

The efficacy and safety profile of mirikizumab was consistent across subgroups, i.e. age, gender, body weight, disease activity severity at baseline and region. The effect size may vary.

At week 40, a greater proportion of patients were in clinical response (defined as decrease in the MMS of ≥ 2 points and ≥ 30 % decrease from baseline, and a decrease of ≥ 1 point in the RB subscore from baseline or a RB score of 0 or 1) in the mirikizumab responder group re-randomised to mirikizumab (80 %) compared to the mirikizumab responder group re-randomised to placebo (49 %).

Week 24 responders to mirikizumab extended induction (LUCENT-2)

For the mirikizumab patients who were not in response at week 12 of LUCENT-1 and received open-label additional 3 doses of 300 mg mirikizumab IV every 4 weeks (Q4W) 53.7 % achieved clinical response at week 12 of LUCENT-2 and 52.9 % mirikizumab patients continued to maintenance receiving 200 mg mirikizumab Q4W SC, and among these patients 72.2 % achieved clinical response and 36.1 % achieved clinical remission at week 40.

Recapture of efficacy after loss of response to mirikizumab maintenance (LUCENT-2) 19 patients who experienced a first loss of response (5.2 %) between week 12 and 28 of LUCENT-2 received open-label mirikizumab rescue dosing with 300 mg mirikizumab Q4W IV for 3 doses and 12 of these patients (63.2 %) achieved symptomatic response and 7 patients (36.8 %) achieved

Endoscopic normalisation at week 40

symptomatic remission after 12 weeks.

Normalisation of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0. At week 40 of LUCENT-2, endoscopic normalisation was achieved in 81/365 (22.2 %) of patients treated with mirikizumab and in 24/179 (13.4 %) of patients in placebo group.

Histologic outcomes

At week 12 greater proportions of patients in the mirikizumab group achieved histologic improvement (39.2 %) compared with patients in the placebo group (20.7 %). At week 40 histologic remission was observed with more patients in the mirikizumab group (48.5 %) as compared to placebo (24.6 %).

Stable maintenance of symptomatic remission

Stable maintenance of symptomatic remission was defined as the proportion of patients in symptomatic remission for at least 7 out of 9 visits from week 4 to week 36 and in symptomatic remission at week 40 among patients in symptomatic remission and clinical response at week 12 of LUCENT-1. At week 40 of LUCENT-2, the proportion of patients achieving stable maintenance of symptomatic remission was greater in patients treated with mirikizumab (69.7 %) versus placebo (38.4 %).

Health-related quality of life

At week 12 of LUCENT-1, patients receiving mirikizumab showed significantly greater clinically relevant improvements on the Inflammatory Bowel Disease Questionnaire (IBDQ) total score ($p \le 0.001$) when compared to placebo. IBDQ response was defined as at least a 16-point improvement from baseline in IBDQ score and IBDQ remission was defined as a score of at least 170. At week 12 of LUCENT-1, 57.5 % of mirikizumab-treated patients achieved IBDQ remission versus 39.8 % with placebo (p < 0.001) and 72.7 % of mirikizumab-treated patients achieved patients achieved IBDQ response versus 55.8 % in placebo. In LUCENT-2 at week 40, 72.3 % of mirikizumab-treated patients achieved maintenance of IBDQ remission versus 43.0 % placebo treated patients and 79.2 % mirikizumab treated patients achieved IBDQ response versus 49.2 % of placebo treated patients.

Patient reported outcomes

Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab in LUCENT-1. Patients receiving mirikizumab achieved significant bowel urgency remission compared with patients in the placebo group at week 12 in LUCENT-1 (22.1 % vs 12.3 %), and week 40 in LUCENT-2 (42.9 % vs 25 %). Patients receiving mirikizumab showed significant improvements in fatigue as early as week 2 of LUCENT-1 and the improvements were maintained at week 40 of LUCENT-2. As early as week 4 there was also a significantly greater reduction in abdominal pain.

Hospitalisations and ulcerative colitis related surgeries

Through week 12 of LUCENT-1, the proportion of patients with UC-related hospitalisations were 0.3 % (3/868) in the mirikizumab and 3.4 % (10/294) in the placebo group. UC-related surgeries were reported in 0.3 % (3/868) patients receiving mirikizumab and 0.7 % (2/294) patients in the placebo group. There were no UC-related hospitalisations and no UC-related surgeries in LUCENT-2 in the mirikizumab arm.

Crohn's disease

The efficacy and safety of mirikizumab was evaluated in a randomized, double-blind, placebo- and active controlled treat-through designed clinical study VIVID-1 in adult patients with moderately to severely active Crohn's disease who had an inadequate response with, loss of response, or intolerance to corticosteroids, immunomodulators (e.g. azathioprine, 6-mercaptopurine), or a biologic treatment (e.g. TNF α antagonist or integrin receptor antagonist). This study included a mirikizumab 12-week intravenous infusion induction period followed by a 40-week subcutaneous injection maintenance period. This study also included an ustekinumab comparator arm in the induction and maintenance periods.

VIVID-1

In VIVID-1, efficacy was evaluated in 1065 patients who were randomized 6:3:2 to receive mirikizumab 900 mg by intravenous infusion (IV) at week 0, week 4, and week 8 followed by a maintenance dose of 300 mg by subcutaneous injection (SC) at week 12 and then every 4 weeks (Q4W) for 40 weeks, ustekinumab approximately 6 mg/kg by IV administration at week 0 followed by 90 mg SC administration every 8 weeks (Q8W) starting at week 8, or placebo. Patients randomised to placebo at baseline who achieved clinical response by Patient-Reported Outcome (PRO) at week 12 (defined as at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) with neither score worse than baseline) remained on placebo. Patients randomized to placebo at

baseline who did not achieve clinical response by PRO at week 12 received mirikizumab 900 mg by IV infusion at week 12, week 16, and week 20 followed by a maintenance dose of 300 mg Q4W SC at week 24 through week 48.

Disease activity at baseline was assessed by (1) the unweighted daily average of SF (2), the unweighted daily average AP (ranging from 0 to 3) and (3) Simple Endoscopic Score for Crohn's disease (SES-CD) (ranging from 0 to 56).

Moderately to severely active CD was defined by SF \geq 4 and/or AP \geq 2 and SES-CD \geq 7 (centrally read) for patients with ileal-colonic and isolated colonic disease or \geq 4 for patients with isolated ileal disease. At baseline patients had a median SF of 6, AP of 2 and SES-CD of 12.

Patients had a mean age of 36 years (range 18 to 76 years); 45 % were female; and 72 % identified as White, 25 % as Asian, 2 % as Black, and 1 % as another racial group. Patients were permitted to use stable doses of corticosteroids, immunomodulators (e.g., 6-mercatopurine, azathioprine or methotrexate) and/or aminosalicylates. At baseline, 31 % of patients were receiving oral corticosteroids, 27 % were receiving immunomodulators, and 44 % were receiving aminosalicylates.

At baseline, 49 % had a loss of response, inadequate response, or intolerance to one or more biologic therapy (prior biologic failure); 46 % of patients had failed TNF α inhibitors and 11 % had failed vedolizumab therapy.

The co-primary endpoints of VIVID-1 were (1) clinical response by PRO at week 12 and endoscopic response at week 52 versus placebo and (2) clinical response by PRO at week 12 and clinical remission by Crohn's Disease Activity Index (CDAI) at week 52; the results for the co-primary endpoints and the major secondary endpoints at week 52 versus placebo are provided in table 4. The major secondary endpoints at week 12 versus placebo are provided in table 5.

| | Placebo n=199 | | Mirikizumab 300 mg SC injection ^a n=579 | | Treatment Difference from Placebo ^b (99.5% CI) |
|--|---------------------|---------|---|------|--|
| | n | % | n | % | |
| Co- | orimary en | dpoints | | | |
| Clinical response by PRO ^c at week 12 and | 18/199 | 9 % | 220/579 | 38 % | 29% ^e (21 %, 37 %) |
| endoscopic response ^d at week 52 | | | | | |
| Without prior biologic failure | 12/102 | 12 % | 117/298 | 39 % | |
| Prior biologic failure ^f | 6/97 | 6 % | 103/281 | 37 % | |
| Clinical response by PRO ^c at week 12 and | 39/199 | 20 % | 263/579 | 45 % | 26 % ^e (16 %, 36 %) |
| clinical remission by CDAI ^g at week 52 | | | | | |
| Without prior biologic failure | 27/102 | 27 % | 141/298 | 47 % | |
| Prior biologic failure ^f | 12/97 | 12 % | 122/281 | 43 % | |
| Add | litional en | dpoints | | | |
| Endoscopic response ^d at week 52 | 18/199 ^h | 9 % | 280/579 | 48 % | 39 % ^e (31 %, 47 %) |
| Without prior biologic failure | $12/102^{h}$ | 12 % | 154/298 | 52 % | |
| Prior biologic failure ^f | 6/97 ^h | 6 % | 126/281 | 45 % | |
| Clinical remission by CDAI ^h at week 52 | 39/199 ^h | 20 % | 313/579 | 54 % | 35 % ^e (25 %, 44 %) |
| Without prior biologic failure | 27/102 ^h | 27 % | 169/298 | 57 % | |
| Prior biologic failure ^f | 12/97 ^h | 12 % | 144/281 | 51 % | |
| Clinical response by PRO ^c at week 12 and | 39/199 | 20 % | 263/579 | 45 % | 26 % ^e (16 %, 36 %) |
| clinical remission by PRO ⁱ at week 52 | | | | | |
| Clinical response by PRO ^c at week 12 and | 8/199 | 4 % | 136/579 | 24 % | 19 % ^e (13 %, 26 %) |
| endoscopic remission ^j at week 52 | | | | | |
| Clinical response by PRO ^c at week 12 and | 37/199 | 19 % | 253/579 | 44 % | 25 % ^e (15 %, 35 %) |
| corticosteroid-free clinical remission by | | | | | |
| CDAI ^{g, k} at Week 52 | | | | | |

| Table 4. Proportion of patients with C | Crohn's disease meeting | efficacy endpoints in | VIVID-1 at |
|--|-------------------------|-----------------------|------------|
| week 52 | | | |

Abbreviations: AP = abdominal pain; CDAI = Crohn's Disease Activity Index; CI = confidence interval; PRO = 2 of the patient-reported items of the CDAI (SF and AP); SES-CD = Simple Endoscopic Score for Crohn's Disease; SF = stool frequency.

- a Following mirikizumab 900 mg as an IV infusion at week 0, week 4, and week 8 patients received mirikizumab 300 mg as a SC injection at week 12 and every 4 weeks thereafter for up to an additional 40 weeks.
- b For binary endpoints adjusted treatment difference was based on Cochran-Mantel-Haenszel method adjusted for baseline covariates.
- c Clinical response by PRO is defined as at least a 30% decrease in SF and/or AP and neither score worse than baseline.
- d Endoscopic response is defined as ≥50% reduction from baseline in SES-CD total score, based on central reading.
- e p < 0.000001
- f Prior biologic failure includes loss of response, inadequate response, or intolerance to one or more biologic therapy (e.g. TNFα antagonist or integrin receptor antagonist).
- g Clinical remission by CDAI is defined as CDAI total score < 150.
- h Placebo sample size includes all patients randomized to placebo at baseline. Placebo patients that did not achieve clinical response by PRO at week 12 were considered non-responders at week 52.
- i Clinical remission by PRO is defined as $SF \le 3$ and not worse than baseline (according to the Bristol Stool Scale Category 6 or 7) and $AP \le 1$ and not worse than baseline.
- j Endoscopic remission is defined as SES-CD Total Score ≤ 4 and at least a 2-point reduction versus baseline and no subscore >1 in any individual variable, based on central reading.
- k Corticosteroid-free is defined as patients who were corticosteroid-free from week 40 to week 52.

Bowel urgency remission

Bowel urgency remission was assessed during VIVID-1 with an urgency numeric rating scale (NRS) of 0 to 10. A greater proportion of patients with a baseline urgency NRS weekly average score \geq 3 treated with mirikizumab compared to placebo achieved clinical response by PRO at week 12 and an urgency NRS weekly average score of \leq 2 at week 52 (33 % versus 11 %).

Table 5. Proportion of patients with Crohn's disease meeting efficacy endpoints in VIVID -1 at week 12

| Endpoint | Placebo n=199 | | Mirikizur 900 m IV infusi n=579 | nab g on ^a | Treatment Difference from Placebo ^b (99.5% CI) |
|--|------------------|------|--|-----------------------------|--|
| | n | % | n | % | |
| Clinical response by PRO ^c | 103/199 | 52 % | 409/579 | 71 % | 19 % ^e (8 %, 30 %) |
| Clinical remission by CDAI ^g | 50/199 | 25 % | 218/579 | 38 % | 12 % ^h (2 %, 23 %) |
| Endoscopic response ^d | 25/199 | 13 % | 188/579 | 32 % | 20 % ^e (11 %, 28 %) |
| Endoscopic remission ^j | 14/199 | 7 % | 102/579 | 18 % | 11 % ^h (4 %, 17 %) |
| Change from baseline in FACIT-fatigue ^h | LS Mean | SE | LS Mean | SE | |
| | 2.6 | 0.61 | 5.9 | 0.36 | $3.2^{\rm f}(1.2, 5.2)$ |

Abbreviations: FACIT-fatigue = Functional Assessment of Chronic Illness Therapy – fatigue;

LS Mean = Least Square Mean; SE = Standard Error; others see above table 4.

- a Weeks 0, 4, 8
- b see table 4. Also see footnote k.
- c, d, e, g, j see table 4
- f p-value < 0.005
- h For change from baseline in FACIT-fatigue, the LS means and treatment difference were based on ANCOVA model adjusted for baseline FACIT-fatigue and other covariates. At baseline, mean FACIT-fatigue values were similar across treatment groups and ranged from 32.3-31.5.

Improvements in clinical remission by CDAI were observed as early as week 4 in a greater proportion of patients treated with mirikizumab compared to placebo.

Reductions in abdominal pain were observed as early as week 4 and in stool frequency as early as week 6 in patients treated with mirikizumab compared to placebo.

The efficacy and safety profile of mirikizumab was consistent across subgroups, i.e. age, gender, body weight, disease activity severity at baseline and region. The effect size may vary.

Active comparator arm

At week 52, mirikizumab demonstrated non-inferiority (pre-specified margin of -10%) to ustekinumab on clinical remission by CDAI (mirikizumab 54 %; ustekinumab 48 %). Superiority over ustekinumab in week 52 endoscopic response was not achieved (mirikizumab 48 %, ustekinumab 46 %).

Histologic outcome

Across all five intestinal segments 44 % of patients on mirikizumab achieved-the composite endpoint of clinical response by PRO at week 12 and histologic response at week 52 compared to 16 % of patients on placebo. Histologic response at week 52 was achieved by 58 % of patients compared to 49% on ustekinumab.

Health-related quality of life

At week 12, change in the Inflammatory Bowel Disease Questionnaire (IBDQ) score was 36.9 for mirikizumab and 17.4 for placebo; IBDQ response and remission were achieved in 69 % and 52 %

of mirikizumab-treated patients versus 45 % and 28 % in placebo patients respectively. These improvements were maintained at week 52.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Omvoh in one or more subsets of the paediatric population in the treatment of ulcerative colitis and Crohn's disease (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

There was no apparent accumulation in serum mirikizumab concentration over time when given subcutaneously every 4 weeks.

Exposure

Ulcerative colitis

Mean (coefficient of variation in %) C_{max} and area under the curve (AUC) after induction dosing (300 mg every 4 weeks administered by intravenous infusion) in patients with ulcerative colitis were 99.7 µg/mL (22.7 %) and 538 µg*day/mL (34.4 %), respectively. The mean (CV %) C_{max} and AUC after maintenance dosing (200 mg every 4 weeks by subcutaneous injection) were 10.1 µg/mL (52.1 %) and 160 µg*day/mL (57.6 %), respectively.

Crohn's disease

Mean (coefficient of variation in %) C_{max} and area under the curve (AUC) after induction dosing (900 mg every 4 weeks administered by intravenous infusion) in patients with Crohn's disease were 332 µg/mL (20.6 %) and 1820 µg*day/mL (38.1 %), respectively. The mean (CV %) C_{max} and AUC after maintenance dosing (300 mg every 4 weeks by subcutaneous injection) were 13.6 µg/mL (48.1 %) and 220 µg*day/mL (55.9 %), respectively.

Absorption

Following subcutaneous dosing of mirikizumab for ulcerative colitis, median (range) Tmax was 5 (3.08-6.75) days post dose and geometric mean (CV%) absolute bioavailability was 44 % (34%). Following subcutaneous dosing of mirikizumab for Crohn's disease, median (range) Tmax was 5 (3 to 6.83) days post dose and geometric mean (CV%) absolute bioavailability was 36.3% (31%).

Injection site location did not significantly influence absorption of mirikizumab.

Distribution

The geometric mean total volume of distribution was 4.83 L (21 %) in patients with ulcerative colitis and 4.40 L (14 %) in patients with Crohn's disease.

Biotransformation

Mirikizumab is a humanised IgG4 monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgGs.

Elimination

In the population PK analysis, geometric mean (CV %) clearance was 0.0229 L/hr (34 %) and the geometric mean half-life is approximately 9.3 days (40 %) in patients with ulcerative colitis. The geometric mean (CV%) clearance was 0.0202 L/hr (38 %) and the geometric mean (CV %) half-life

is also approximately 9.3 days (26 %) in patients with Crohn's disease. Clearance is independent of dose.

Dose proportionality

Mirikizumab exhibited linear pharmacokinetics with dose-proportional increase in exposure over a dose range of 5 to 2 400 mg given as an intravenous infusion or over a dose range of 120 to 400 mg given as a subcutaneous injection in patients with ulcerative colitis or Crohn's disease or in healthy volunteers.

Special populations

Population pharmacokinetic analysis showed that age, sex, weight, or race/ethnicity did not have a clinically meaningful effect on the pharmacokinetics of mirikizumab (see also section 4.8, "immunogenicity"). Among the 1 362 subjects with ulcerative colitis exposed to mirikizumab in Phase 2 and Phase 3 studies, 99 (7.3 %) patients were 65 years or older and 11 (0.8 %) patients were 75 years or older.

Renal or hepatic impairment

Specific clinical pharmacology studies to evaluate the effects of renal impairment and hepatic impairment on the pharmacokinetics of mirikizumab have not been conducted.

In patients with ulcerative colitis, population pharmacokinetic analysis showed that creatinine clearance (range of 36.2 to 291 mL/min) or total bilirubin (range of 1.5 to 29 μ mol/L) did not affect mirikizumab pharmacokinetics.

In patients with Crohn's disease, population pharmacokinetic analysis showed that creatinine clearance (range of 26.5 to 269 mL/min) or total bilirubin (range of 1.5 to 36 μ mol/L) did not affect mirikizumab pharmacokinetics.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction and development.

Carcinogenesis / mutagenesis

Non-clinical studies have not been conducted to evaluate the carcinogenic or mutagenic potential of mirikizumab.

Impairment of fertility

No reproductive organ weight or histopathology effects were observed in sexually mature cynomolgus monkeys that received mirikizumab once weekly for 26 weeks, at a dose of 100 mg/kg (at least 20 times the human maintenance dose).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium citrate dihydrate (E 331) Citric acid, anhydrous (E 330) Sodium chloride Polysorbate 80 (E 433) Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

Omvoh should not be administered concomitantly in the same intravenous line with other medicinal products.

6.3 Shelf life

2 years.

After dilution

Chemical and physical in-use stability has been demonstrated for diluted infusion solution prepared with sodium chloride 9 mg/mL (0.9 %) solution for 96 hours at 2 °C to 8 °C of which not more than 10 hours are permitted at non-refrigerated temperatures not to exceed 25 °C, starting from the time of vial puncture.

Chemical and physical in-use stability has been demonstrated for diluted infusion solution prepared with 5 % glucose for 48 hours at 2 °C to 8 °C of which not more than 5 hours are permitted at non-refrigerated temperatures not to exceed 25 °C, starting from the time of vial puncture.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Keep the diluted solution away from direct heat or light. Do not freeze the diluted solution.

6.4 Special precautions for storage

Unopened vial

Store in a refrigerator (2 °C - 8 °C). Do not freeze. Keep the vial in the outer carton in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

15 mL concentrate in a type I clear glass vial with a chlorobutyl rubber stopper, an aluminium seal and polypropylene flip top.

Pack sizes of 1 vial and 3 vials. Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Do not use Omvoh that has been frozen.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Dilution prior to intravenous infusion

- 1. Each vial is for single use only.
- 2. Prepare the infusion solution using aseptic technique to ensure the sterility of the prepared solution.
- 3. Inspect the content of the vial. The concentrate should be clear, colourless to slightly yellow and free of visible particles. Otherwise, it should be discarded.
- 4. Prepare the infusion bag for treatment of either ulcerative colitis or Crohn's disease as specified below. Note that there are unique instructions and volumes specified for each indication.

Ulcerative colitis: one 15 mL vial (300 mg)

Withdraw 15 mL of the mirikizumab vial (300 mg) using an appropriately sized needle (18 to 21 gauge is recommended) and transfer to the infusion bag. If administered for the treatment of ulcerative colitis, the concentrate should be diluted only in infusion bags (bag size ranging from 50 - 250 mL) containing either sodium chloride 9 mg/mL (0.9 %) solution for injection or 5 % glucose solution for injection. The final concentration after dilution is approximately 1.1 mg/mL to approximately 4.6 mg/mL.

Crohn's disease: three 15 mL vials; total volume = 45 mL (900 mg)

First, withdraw and discard 45 mL of diluent from the infusion bag. Next, withdraw 15 mL from each of the three mirikizumab vials (900 mg) and transfer to the infusion bag, using an appropriately sized syringe and needle (18 to 21 gauge is recommended). If administered for the treatment of Crohn's disease, the concentrate should be diluted only in infusion bags (bag size ranging from 100-250 mL) containing either sodium chloride 9 mg/mL (0.9 %) solution for injection or 5 % glucose solution for injection.

The final concentration after dilution is approximately 3.6 mg/mL to approximately 9 mg/mL.

5. Gently invert the infusion bag to mix. Do not shake the prepared bag.

7. MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/001 EU/1/23/1736/011

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 26 May 2023

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>https://www.ema.europa.eu</u>.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg solution for injection in pre-filled syringe Omvoh 100 mg solution for injection in pre-filled pen Omvoh 200 mg solution for injection in pre-filled syringe Omvoh 200 mg solution for injection in pre-filled pen

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Omvoh 100 mg solution for injection in pre-filled syringe

Each pre-filled syringe contains 100 mg mirikizumab in 1 mL solution.

Omvoh 100 mg solution for injection in pre-filled pen

Each pre-filled pen contains 100 mg mirikizumab in 1 mL solution.

Omvoh 200 mg solution for injection in pre-filled syringe

Each pre-filled syringe contains 200 mg mirikizumab in 2 mL solution.

Omvoh 200 mg solution for injection in pre-filled pen

Each pre-filled pen contains 200 mg mirikizumab in 2 mL solution.

Mirikizumab is a humanised monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection (injection)

The solution is a clear and colourless to slightly yellow solution with a pH of approximately 5.5 and an osmolarity of approximately 300 mOsm/L.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Ulcerative colitis

Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Crohn's disease

Omvoh is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

4.2 Posology and method of administration

This medicinal product is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of ulcerative colitis or Crohn's disease. Omvoh 100 mg solution for injection and Omvoh 200 mg solution for injection should only be used for the subcutaneous maintenance doses.

Posology

Ulcerative colitis

The recommended mirikizumab dose regimen has 2 parts.

Induction dose

The induction dose is 300 mg by intravenous infusion for at least 30 minutes at weeks 0, 4 and 8. (See Summary of Product Characteristics for Omvoh 300 mg concentrate for solution for infusion, section 4.2.)

Maintenance dose

The maintenance dose is 200 mg (i.e. two pre-filled syringes or two pre-filled pens) by subcutaneous injection every 4 weeks after completion of induction dosing.

Patients should be evaluated after the 12-week induction dosing and if there is adequate therapeutic response, transition to maintenance dosing. For patients who do not achieve adequate therapeutic benefit at week 12 of induction dosing, mirikizumab 300 mg by intravenous infusion may be continued at weeks 12, 16 and 20 (extended induction therapy). If therapeutic benefit is achieved with the additional intravenous therapy, patients may initiate mirikizumab subcutaneous maintenance dosing (200 mg) every 4 weeks, starting at week 24. Mirikizumab should be discontinued in patients who do not show evidence of therapeutic benefit to extended induction therapy by week 24.

Patients with loss of therapeutic response during maintenance treatment may receive 300 mg mirikizumab by intravenous infusion every 4 weeks, for a total of 3 doses (re-induction). If clinical benefit is achieved from this additional intravenous therapy, patients may resume mirikizumab subcutaneous dosing every 4 weeks. The efficacy and safety of repeated re-induction therapy have not been evaluated.

Missed dose

In case of a missed dose, instruct patients to inject as soon as possible. Thereafter, resume dosing every 4 weeks.

Crohn's Disease

The recommended mirikizumab dose regimen has 2 parts.

Induction dose

The induction dose is 900 mg (3 vials of 300 mg each) by i.v. infusion for at least 90 minutes at weeks 0, 4 and 8.

(See Summary of Product Characteristics for Omvoh 300 mg concentrate for solution for infusion, section 4.2.)

Maintenance dose

The maintenance dose is 300 mg (i.e. one pre-filled syringe or pre-filled pen of 100 mg and one pre-filled syringe or pre-filled pen of 200 mg) by subcutaneous injection every 4 weeks after completion of induction dosing.

The injections may be administered in any order.

The 200 mg pre-filled syringe and the 200 mg pre-filled pen are only for the treatment of Crohn's disease.

Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by week 24.

Missed dose

In case of a missed dose, instruct patients to inject as soon as possible. Thereafter, resume dosing every 4 weeks.

Special populations

<u>Elderly</u>

No dose adjustment is required (see section 5.2). There is limited information in subjects aged \geq 75 years.

Renal or hepatic impairment

Omvoh has not been studied in these patient populations. These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary (see section 5.2).

Paediatric population

The safety and efficacy of Omvoh in children and adolescents aged 2 to less than 18 years have not yet been established. No data are available.

There is no relevant use of Omvoh in children below 2 years for the indication of ulcerative colitis or Crohn's disease.

Method of administration

For subcutaneous injection only.

Sites for injection include the abdomen, thigh, and back of the upper arm. After training in subcutaneous injection technique, a patient may self-inject with mirikizumab. Patients should be instructed to inject in a different location every time. For example, if the first injection was in the abdomen, the second injection—to complete a full dose—could be in another area of the abdomen.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Clinically important active infections (active tuberculosis).

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity reactions

In clinical studies, hypersensitivity reactions have been reported. Most were mild or moderate, severe reactions were uncommon (see section 4.8). If a serious hypersensitivity reaction, including anaphylaxis, occurs, mirikizumab must be discontinued immediately and appropriate therapy must be initiated.

Infections

Mirikizumab may increase the risk of severe infection (see section 4.8). Treatment with mirikizumab should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated (see section 4.3). The risks and benefits of treatment should be considered prior to initiating use of mirikizumab in patients with a chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops, discontinuation of mirikizumab should be considered until the infection resolves.

Pre-treatment evaluation for tuberculosis

Prior to initiating treatment, patients should be evaluated for tuberculosis (TB) infection. Patients receiving mirikizumab should be monitored for signs and symptoms of active TB during and after treatment. Anti-TB therapy should be considered prior to initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Hepatic enzyme elevations

Cases of drug-induced liver injury (including one case meeting Hy's Law criteria) occurred in patients receiving mirikizumab in clinical trials. Liver enzymes and bilirubin should be evaluated at baseline and monthly during induction (including extended induction period, if applicable). Thereafter, liver enzymes and bilirubin should be monitored (every 1 - 4 months) according to standard practice for patient management and as clinically indicated. If increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) are observed and drug-induced liver injury is suspected, mirikizumab must be discontinued until this diagnosis is excluded.

Immunisations

Prior to initiating therapy with mirikizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. Avoid use of live vaccines in patients treated with mirikizumab. No data are available on the response to live or non-live vaccines.

Excipients with known effect

<u>Sodium</u>

Ulcerative colitis

This medicinal product contains less than 1 mmol sodium (23 mg) per 200 mg dose, that is to say essentially "sodium-free".

Crohn's disease

This medicinal product contains less than 1 mmol sodium (23 mg) per 300 mg dose, that is to say essentially "sodium-free".

Polysorbate

This medicinal product contains 0.3 mg/mL of polysorbate 80 in each pen or syringe which is equivalent to 0.6 mg for the maintenance dose to treat ulcerative colitis and equivalent to 0.9 mg for the maintenance dose to treat Crohn's disease. Polysorbates may cause allergic reactions.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

In clinical studies, concomitant use of corticosteroids or oral immunomodulators did not influence the safety of mirikizumab.

Population pharmacokinetic data analyses indicated that the clearance of mirikizumab was not impacted by concomitant administration of 5-ASAs (5-aminosalicylic acid), corticosteroids or oral immunomodulators (azathioprine, 6-mercaptopurine, thioguanine, and methotrexate).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment.

Pregnancy

There is a limited amount of data from the use of mirikizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Omvoh during pregnancy.

Breast-feeding

It is unknown whether mirikizumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Omvoh therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

The effect of mirikizumab on human fertility has not been evaluated (see section 5.3).

4.7 Effects on ability to drive and use machines

Omvoh has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions are upper respiratory tract infections (9.8 %, most frequently nasopharyngitis), headache (3.2 %), rash (1.3 %) and injection site reactions (10.8 %, maintenance period).

Tabulated list of adverse reactions

Adverse reactions from clinical studies (Table 1) are listed by MedDRA system organ class. The frequency category for each reaction is based on the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to < 1/10); uncommon ($\geq 1/1000$ to < 1/100); rare ($\geq 1/10000$ to < 1/1000); very rare (< 1/10000).

Table 1: Adverse reactions

| MedDRA System organ class | Frequency | Adverse reaction |
|--------------------------------|-------------|---|
| Infections and infestations | Common | Upper respiratory tract infections ^a |
| | Uncommon | Herpes zoster |
| Immune system disorders | Uncommon | Infusion-related hypersensitivity reactions |
| Musculoskeletal and Connective | Common | Arthralgia |
| Tissue Disorders | | |
| Nervous system disorders | Common | Headache |
| Skin and subcutaneous tissue | Common | Rash ^b |
| disorders | | |
| General disorders and | Very common | Injection site reactions ^c |
| administration site conditions | Uncommon | Infusion site reactions ^d |
| Investigations | Uncommon | Alanine aminotransferase increased |
| | Uncommon | Aspartate aminotransferase increased |

^a Includes: acute sinusitis, COVID-19, nasopharyngitis, oropharyngeal discomfort, oropharyngeal pain, pharyngitis, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, and viral upper respiratory tract infection.

^b Includes: rash, rash macular, rash maculo-papular, and rash papular and rash pruritic.

^c Reported during mirikizumab maintenance therapy where mirikizumab treatment is administered as subcutaneous injection.

^{*d*} *Reported during mirikizumab induction therapy where mirikizumab treatment is administered as intravenous infusion.*

Description of selected adverse reactions

Infusion-related hypersensitivity reactions (induction therapy)

Infusion-related hypersensitivity reactions were reported in 0.4 % of mirikizumab-treated patients. All infusion-related hypersensitivity reactions were reported as non-serious.

Injection site reactions (maintenance therapy)

Injection site reactions were reported in 10.8 % of mirikizumab -treated patients. The most frequent reactions were injection site pain, injection site reaction and injection site erythema. These symptoms were reported as non-serious, mild and transient in nature.

The results described above were obtained with the original formulation of Omvoh. In a double blind, 2-arm, randomised, single-dose, parallel design study in 60 healthy subjects comparing 200 mg mirikizumab (2 injections of 100 mg in a pre-filled syringe) of the original formulation with the revised formulation statistically significantly lower VAS pain scores were obtained with the revised (12.6) vs. the original formulation (26.1) 1 minute after injection.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increased

In the first 12 weeks, ALT increased was reported in 0.6 % mirikizumab-treated patients. AST increased was reported by 0.4 % mirikizumab-treated patients. All adverse reactions were reported as mild to moderate in severity and non-serious.

Over all mirikizumab treatment periods in the ulcerative colitis and Crohn's disease clinical development program (including the placebo-controlled and open label induction and maintenance periods), there have been elevations of ALT to \geq 3 x upper limit of normal (ULN) (2.3 %), \geq 5 x ULN (0.7 %) and \geq 10 x ULN (0.2 %) and AST to \geq 3 x ULN (2.2 %), \geq 5 x ULN (0.8 %) and

 \geq 10 x ULN (0.1 %) in patients receiving mirikizumab (see section 4.4). These elevations have been noted with and without concomitant elevations in total bilirubin.

Immunogenicity

In the ulcerative colitis studies, up to 23 % of mirikizumab-treated patients with 12 months of treatment developed anti-drug antibodies, most of which were of low titer and tested positive for neutralising activity. Higher antibody titers in approximately 2 % of subjects treated with mirikizumab were associated with lower serum mirikizumab concentrations and reduced clinical response.

In the Crohn's disease study, 12.7% of mirikizumab-treated patients with 12 months of treatment developed anti-drug antibodies, most of which were of low titer and tested positive for neutralising activity. There was no identified clinically significant effect of anti-drug antibodies on pharmacokinetics or effectiveness of mirikizumab.

No association was found between anti-mirikizumab antibodies and hypersensitivity or injectionrelated events in either the ulcerative colitis or the Crohn's disease studies.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in <u>Appendix V</u>.

4.9 Overdose

Mirikizumab doses up to 2 400 mg intravenously and up to 500 mg subcutaneously have been administered in clinical trials without dose-limiting toxicity. In the event of overdose, the patient must be monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment must be started immediately.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC24

Mechanism of action

Mirikizumab is a humanised IgG4 monoclonal, anti-interleukin-23 (anti-IL-23) antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.

IL-23, a regulatory cytokine, affects the differentiation, expansion, and survival of T cell subsets, (e.g., Th17 cells and Tc17 cells) and innate immune cell subsets, which represent sources of effector cytokines, including IL-17A, IL-17F and IL-22 that drive inflammatory disease. In humans, selective blockade of IL-23 was shown to normalise production of these cytokines.

Pharmacodynamic effects

Inflammatory biomarkers were measured in the phase 3 ulcerative colitis and Crohn's disease studies. Mirikizumab administered intravenously every 4 weeks during induction dosing significantly reduced levels of fecal calprotectin and C-reactive protein from baseline to week 12. Also, mirikizumab administered subcutaneously every 4 weeks during maintenance dosing sustained significantly reduced levels of fecal calprotectin and C-reactive protein up to 52 weeks.

Clinical efficacy and safety

Ulcerative colitis

The efficacy and safety of mirikizumab was evaluated in adult patients with moderately to severely active ulcerative colitis in two randomised, double-blind, placebo-controlled, multicentre studies. Enrolled patients had a confirmed diagnosis of ulcerative colitis for at least 3 months and moderately to severely active disease, defined as a modified Mayo score of 4 to 9, including a Mayo endoscopy subscore ≥ 2 . Patients had to have failed (defined as loss of response, inadequate response or intolerance) corticosteroids or immunomodulators (6-mercaptopurine, azathioprine) or at least one biologic (a TNF α antagonist and/or vedolizumab) or tofacitinib.

LUCENT-1 was an intravenous induction study with treatment of up to 12 weeks, followed by a 40 week subcutaneous randomised withdrawal maintenance study (LUCENT-2), representing at least 52 weeks of therapy. Mean age was 42.5 years. 7.8 % of patients were \geq 65 of age and 1.0 % of patients \geq 75 of age. 59.8 % were men; 40.2 % were women. 53.2 % had severely active disease with a modified Mayo score 7 to 9.

Efficacy results presented for LUCENT-1 and LUCENT-2 were based on central reading of endoscopies and histology.

LUCENT-1

LUCENT-1 included 1 162 patients in the primary efficacy population. Patients were randomised to receive a dose of 300 mg mirikizumab via intravenous infusion or placebo, at week 0, week 4 and week 8 with a 3:1 treatment allocation ratio. The primary endpoint for the induction study was the proportion of subjects in clinical remission [modified Mayo score (MMS) defined as: Stool frequency (SF) subscore = 0 or 1 with $a \ge 1$ -point decrease from baseline, and rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)] at week 12.

Patients in these studies may have received other concomitant therapies including aminosalicylates (74.3 %), immunomodulatory agents (24.1 % such as azathioprine, 6-mercaptopurine or methotrexate), and oral corticosteroids (39.9 %; prednisone daily dose up to 20 mg or equivalent) at a stable dose prior to and during the induction period. Per protocol oral corticosteroids were tapered after induction.

Of the primary efficacy population, 57.1 % were biologic-naive and tofacitinib-naive. 41.2 % of patients had failed a biologic or tofacitinib. 36.3 % of the patients had failed at least 1 prior anti-TNF therapy, 18.8 % had failed vedolizumab and 3.4 % of patients had failed tofacitinib. 20.1 % had failed more than one biologic or tofacitinib. An additional 1.7 % had previously received but had not failed a biologic or tofacitinib.

In LUCENT-1 a significantly greater proportion of patients were in clinical remission in the mirikizumab treated group compared to placebo at week 12 (Table 2). As early as week 2, mirikizumab-treated patients achieved a greater reduction in RB subscores and decreases in SF subscores.

| Table 2: Summary of key efficacy outcomes in LUCENT-1 (week 12 unl | less indicated |
|--|----------------|
| otherwise) | |

| | Placebo n = 294 | | Mirikiz n = | umab IV 868 | Treatment |
|----------------------------------|--------------------|--------|----------------|----------------|----------------------------|
| | n | % | n | % | and 99.875 % CI |
| Clinical remission* ¹ | 39 | 13.3 % | 210 | 24.2 % | 11.1 % (3.2 %, 19.1 %)° |

| Patients who were biologic and JAK-inhibitor naïve ^a | 27/171 | 15.8 % | 152/492 | 30.9 % | |
|---|--------|--------|---------|--------|---|
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/118 | 8.5 % | 55/361 | 15.2 % | |
| Alternate clinical remission* ² | 43 | 14.6 % | 222 | 25.6 % | 11.1 % (3.0 %, 19.3 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 31/171 | 18.1 % | 160/492 | 32.5 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/118 | 8.5 % | 59/361 | 16.3 % | |
| Clinical response* ³ | 124 | 42.2 % | 551 | 63.5 % | 21.4 % (10.8 %, 32.0 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 86/171 | 50.3 % | 345/492 | 70.1 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 35/118 | 29.7 % | 197/361 | 54.6 % | |
| Endoscopic improvement* ⁴ | 62 | 21.1 % | 315 | 36.3 % | 15.4 % (6.3 %, 24.5 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 48/171 | 28.1 % | 226/492 | 45.9 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 12/118 | 10.2 % | 85/361 | 23.5 % | |
| Symptomatic remission (week 4)* ⁵ | 38 | 12.9 % | 189 | 21.8 % | 9.2 % (1.4 %, 16.9 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 26/171 | 15.2 % | 120/492 | 24.4 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/118 | 8.5 % | 67/361 | 18.6 % | |
| Symptomatic remission* ⁵ | 82 | 27.9 % | 395 | 45.5 % | 17.5 % (7.5 %, 27.6 %)° |
| Patients who were biologic and JAK-inhibitor naïve ^a | 57/171 | 33.3 % | 248/492 | 50.4 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 22/118 | 18.6 % | 139/361 | 38.5 % | |
| Histo-endoscopic mucosal improvement ^{*6} | 41 | 13.9 % | 235 | 27.1 % | 13.4 % (5.5 %, 21.4 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 32/171 | 18.7 % | 176/492 | 35.8 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 8/118 | 6.8 % | 56/361 | 15.5 % | |
| | | | | | |

| | Placebo n = 294 | | Mirikiz n = | zumab IV = 868 | Treatment |
|---|--------------------|-------------------|----------------|-------------------|--------------------------|
| | LS mean | Standard error | LS mean | Standard error | and 99.875 % CI |
| Bowel urgency severity*7 | -1.63 | 0.141 | -2.59 | 0.083 | -0.95 (-1.47, -0.44)° |
| Patients who were biologic and JAK-inhibitor naïve ^a | -2.08 | 0.174 | -2.72 | 0.101 | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | -0.95 | 0.227 | -2.46 | 0.126 | |

Abbreviations: CI = confidence interval; IV = intravenous; LS = least square

- *¹ Clinical remission is based on the modified Mayo score (MMS) and is defined as: Stool frequency (SF) subscore = 0 or 1 with $a \ge 1$ -point decrease from baseline, and Rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)
- *² Alternate clinical remission is based on the modified Mayo score (MMS) and is defined as: Stool frequency (SF) subscore = 0 or 1, and Rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)
- *³ Clinical response based on the MMS and is defined as: A decrease in the MMS of ≥ 2 points and ≥ 30 % decrease from baseline, and a decrease of ≥ 1 point in the RB subscore from baseline or a RB score of 0 or 1
- *⁴ Endoscopic improvement defined as: ES = 0 or 1 (excluding friability)
- *⁵ Symptomatic remission defined as: SF = 0, or SF = 1 with $a \ge 1$ -point decrease from baseline, and RB = 0
- *⁶ Histo-endoscopic mucosal improvement defined as achieving both: 1. Histologic improvement, defined using Geboes scoring system with neutrophil infiltration in < 5 % of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue. 2. Endoscopic improvement, defined as ES = 0 or 1 (excluding friability).
- *7 Change from baseline in the Urgency Numeric Rating Scale score
- *a)* An additional 5 patients on placebo and 15 patients on mirikizumab where previously exposed to but did not fail a biologic or JAK-inhibitor.
- b) Loss of response, inadequate response or intolerance.
- c) p < 0.001
- *d) Mirikizumab results in the subgroup of patients who failed more than one biologic or JAK-inhibitor were consistent with results in the overall population.*

LUCENT-2

LUCENT-2 evaluated 544 patients out of the 551 patients who achieved clinical response with mirikizumab in LUCENT-1 at week 12 (see Table 2). Patients were re-randomised in a 2:1 treatment allocation ratio to receive a subcutaneous maintenance regimen of 200 mg mirikizumab or placebo every 4 weeks for 40 weeks (which is 52 weeks from initiation of the induction dose). The primary endpoint for the maintenance study was the proportion of subjects in clinical remission (same definition as in LUCENT-1) at week 40. Corticosteroid tapering was required upon entrance into LUCENT-2 for patients who were receiving corticosteroids during LUCENT-1. Significantly greater proportions of patients were in clinical remission in the mirikizumab-treated group compared to the placebo group at week 40 (see Table 3).

Table 3: Summary of key efficacy measures in LUCENT-2 (week 40; 52 weeks from initiation of the induction dose)

| | Placebo n = 179 | | Mirikizumab SC n = 365 | | Treatment difference and 95 % CI |
|---|--------------------|--------|---------------------------|--------|---|
| | n | % | n | % | |
| Clinical remission* ¹ | 45 | 25.1 % | 182 | 49.9 % | 23.2 % (15.2 %, 31.2 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 35/114 | 30.7 % | 118/229 | 51.5 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/64 | 15.6 % | 59/128 | 46.1 % | |
| Alternate clinical remission* ² | 47 | 26.3 % | 189 | 51.8 % | 24.1 % (16.0 %, 32.2 %) ^c |
| Patients who were biologic and JAK-inhibitor naïve ^a | 37/114 | 32.5 % | 124/229 | 54.1 % | |
| Patients who failed ^b at least one biologic or JAK-inhibitor ^d | 10/64 | 15.6 % | 60/128 | 46.9 % | |

| Maintananaa of aliniaal | | | | | 24.8.0/ |
|--|--------------------|----------|----------------|----------|---|
| $\frac{1}{10000000000000000000000000000000000$ | 24/65 | 36.9 % | 91/143 | 63.6 % | |
| Petiente sube succes higherin | | | | | (10.4 %, 39.2 %) |
| Patients who were biologic | 22/47 | 46.8 % | 65/104 | 62.5 % | |
| Patienta who failed b at least | | | | | |
| one biologic or IAK inhibitor ^d | 2/18 | 11.1 % | 24/36 | 66.7 % | |
| one biblogie of JAR-initibitor | | | | | 21.2.0/ |
| Corticosteroid-free remission* ⁴ | 39 | 21.8 % | 164 | 44.9 % | (12.5.0/20.1.0/) |
| Detients who were high air | | | | | (13.5 %, 29.1 %) |
| and IAK inhibitor païve ^a | 30/114 | 26.3 % | 107/229 | 46.7 % | |
| Patients who failed ^b at least | | | | | |
| one biologic or IAK-inhibitor ^d | 9/64 | 14.1 % | 52/128 | 40.6 % | |
| one biologie of JAR-Innibitor | | | | | 28 5 % |
| Endoscopic improvement* ⁵ | 52 | 29.1 % | 214 | 58.6 % | (20.2.0) $(20.2.0)$ $(20.2.0)$ $(20.2.0)$ |
| Detients who were high aig | | | | | (20.2 %, 30.8 %) |
| and IAK inhibitor poïve ^a | 39/114 | 34.2 % | 143/229 | 62.4 % | |
| Patients who failed ^b at least | | | | | |
| one biologic or IAK-inhibitor d | 13/64 | 20.3 % | 65/128 | 50.8 % | |
| Histo andoscopic mucosal | | | | | 10.0 % |
| remission* ⁶ | 39 | 21.8 % | 158 | 43.3 % | (12, 1, 0) $(27, 0)$ |
| Detients who were biologic | | | | | (12.1 %, 27.6 %) |
| and IAK inhibitor païve ^a | 30/114 | 26.3 % | 108/229 | 47.2 % | |
| Patients who failed ^b at least | | | | | |
| one biologic or IAK-inhibitor d | 9/64 | 14.1 % | 46/128 | 35.9 % | |
| | | | | | 18.1 % |
| Bowel urgency remission ^{*7} | 43/172 | 25.0 % | 144/336 | 42.9 % | $(9.8\%, 26.4\%)^{\circ}$ |
| Patients who were biologic | 21/100 | 20.5.0/ | 0.610.0.6 | 16.6.04 | (,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| and JAK-inhibitor naïve ^a | 31/108 | 28.7 % | 96/206 | 46.6 % | |
| Patients who failed ^b at least | 12/02 | 10.0.0/ | 42/100 | 25.2.0/ | |
| one biologic or JAK-inhibitor ^d | 12/63 | 19.0 % | 43/122 | 35.2 % | |
| | | | | | |
| | Placebo n = 179 | | Mirikizumab SC | | |
| | | | n = | = 365 | I reatment |
| | LS | Standard | LS | Standard | annerence and |
| | mean | error | mean | error | 95 % CI |
| | • | • | | | |
| Bowel urgency severity ^{*8} | 0.54 | 0.000 | 2 00 | 0.120 | -1.06 |
| | -2.74 | 0.202 | -3.80 | 0.139 | (-1.51, -0.61)° |
| Patients who were biologic | 2.00 | 0.000 | 2.02 | 0.153 | |
| and JAK-inhibitor naïve a | -2.69 | 0.233 | -3.82 | 0.153 | |
| Patients who failed ^b at least | 266 | 0.246 | 2.60 | 0.229 | |
| one biologic or JAK-inhibitor ^d | -2.00 | 0.346 | -3.00 | 0.228 | |

Abbreviations: CI = confidence interval; SC = subcutaneous; LS = least square

*^{1, 2} See footnotes on Table 2

- *³ The proportion of patients who were in clinical remission at week 40 among patients in clinical remission at week 12, with clinical remission defined as: Stool frequency (SF) subscore = 0 or SF = 1 with $a \ge 1$ -point decrease from induction baseline, and Rectal bleeding (RB) subscore = 0, and Endoscopic subscore (ES) = 0 or 1 (excluding friability)
- *⁴ Corticosteroid-free remission without surgery, defined as: Clinical remission at week 40, and Symptomatic remission at week 28, and no corticosteroid use for ≥ 12 weeks prior to week 40
- *⁵ Endoscopic improvement defined as: ES = 0 or 1 (excluding friability)
- *⁶ Histo-endoscopic mucosal remission, defined as achieving both: 1. Histologic remission, defined as Geboes subscores of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in

epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration) and 2. Mayo endoscopic score 0 or 1 (excluding friability)

- *⁷ Numeric Rating Scale (NRS) 0 or 1 in patients with urgency NRS \geq 3 at baseline in LUCENT-1
- *8 Change from baseline in the Urgency NRS score
- *a)* An additional 1 patient on placebo and 8 patients on mirikizumab where previously exposed to but did not fail a biologic or JAK-inhibitor.
- b) Loss of response, inadequate response or intolerance.
- c) p < 0.001
- *d) Mirikizumab results in the subgroup of patients who failed more than one biologic or JAK-inhibitor were consistent with results in the overall population.*

The efficacy and safety profile of mirikizumab was consistent across subgroups, i.e. age, gender, body weight, disease activity severity at baseline and region. The effect size may vary.

At week 40, a greater proportion of patients were in clinical response (defined as decrease in the MMS of \geq 2 points and \geq 30 % decrease from baseline, and a decrease of \geq 1 point in the RB subscore from baseline or a RB score of 0 or 1) in the mirikizumab responder group re-randomised to mirikizumab (80 %) compared to the mirikizumab responder group re-randomised to placebo (49 %).

Week 24 responders to mirikizumab extended induction (LUCENT-2)

For the mirikizumab patients who were not in response at week 12 of LUCENT-1 and received open-label additional 3 doses of 300 mg mirikizumab IV every 4 weeks (Q4W) 53.7 % achieved clinical response at week 12 of LUCENT-2 and 52.9 % mirikizumab patients continued to maintenance receiving 200 mg mirikizumab Q4W SC, and among these patients 72.2 % achieved clinical response and 36.1 % achieved clinical remission at week 40.

Recapture of efficacy after loss of response to mirikizumab maintenance (LUCENT-2) 19 patients who experienced a first loss of response (5.2 %) between week 12 and 28 of LUCENT-2 received open label mirikizumab rescue dosing with 300 mg mirikizumab Q4W IV for 3 doses and 12 of these patients (63.2 %) achieved symptomatic response and 7 patients (36.8 %) achieved symptomatic remission after 12 weeks.

Endoscopic normalisation at week 40

Normalisation of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0. At week 40 of LUCENT-2, endoscopic normalisation was achieved in 81/365 (22.2 %) of patients treated with mirikizumab and in 24/179 (13.4 %) of patients in placebo group.

Histologic outcomes

At week 12 greater proportions of patients in the mirikizumab group achieved histologic improvement (39.2 %) compared with patients in the placebo group (20.7 %). At week 40 histologic remission was observed with more patients in the mirikizumab group (48.5 %) as compared to placebo (24.6 %).

Stable maintenance of symptomatic remission

Stable maintenance of symptomatic remission was defined as the proportion of patients in symptomatic remission for at least 7 out of 9 visits from week 4 to week 36 and in symptomatic remission at week 40 among patients in symptomatic remission and clinical response at week 12 of LUCENT-1. At week 40 of LUCENT-2, the proportion of patients achieving stable maintenance of symptomatic remission was greater in patients treated with mirikizumab (69.7 %) versus placebo (38.4 %).

Health-related quality of life

At week 12 of LUCENT-1, patients receiving mirikizumab showed significantly greater clinically relevant improvements on the Inflammatory Bowel Disease Questionnaire (IBDQ) total score

 $(p \le 0.001)$ when compared to placebo. IBDQ response was defined as at least a 16-point improvement from baseline in IBDQ score and IBDQ remission was defined as a score of at least 170. At week 12 of LUCENT-1, 57.5 % of mirikizumab-treated patients achieved IBDQ remission versus 39.8 % with placebo (p < 0.001) and 72.7 % of mirikizumab-treated patients achieved patients achieved IBDQ response versus 55.8 % in placebo. In LUCENT-2 at week 40, 72.3 % of mirikizumab-treated patients achieved maintenance of IBDQ remission versus 43.0 % placebo treated patients and 79.2 % mirikizumab treated patients achieved IBDQ response versus 49.2 % of placebo treated patients.

Patient reported outcomes

Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab in LUCENT-1. Patients receiving mirikizumab achieved significant bowel urgency remission compared with patients in the placebo group at week 12 in LUCENT 1 (22.1 % vs 12.3 %), and week 40 in LUCENT-2 (42.9 % vs 25 %). Patients receiving mirikizumab showed significant improvements in fatigue as early as week 2 of LUCENT-1 and the improvements were maintained at week 40 of LUCENT-2. As early as week 4 there was also a significantly greater reduction in abdominal pain.

Hospitalisations and ulcerative colitis related surgeries

Through week 12 of LUCENT-1, the proportion of patients with UC-related hospitalisations were 0.3 % (3/868) in the mirikizumab and 3.4 % (10/294) in the placebo group. UC-related surgeries were reported in 0.3 % (3/868) patients receiving mirikizumab and 0.7 % (2/294) patients in the placebo group. There were no UC-related hospitalisations and no UC-related surgeries in LUCENT-2 in the mirikizumab arm.

Crohn's disease

The efficacy and safety of mirikizumab was evaluated in a randomized, double-blind, placebo- and active controlled treat-through designed clinical study VIVID-1 in adult patients with moderately to severely active Crohn's disease who had an inadequate response with, loss of response, or intolerance to corticosteroids, immunomodulators (e.g. azathioprine, 6-mercaptopurine), or a biologic treatment (e.g. TNF α antagonist or integrin receptor antagonist). This study included a mirikizumab 12-week intravenous infusion induction period followed by a 40-week subcutaneous injection maintenance period. This study also included an ustekinumab comparator arm in the induction and maintenance periods.

VIVID-1

In VIVID-1, efficacy was evaluated in 1065 patients who were randomized 6:3:2 to receive mirikizumab 900 mg by intravenous infusion (IV) at week 0, week 4, and week 8 followed by a maintenance dose of 300 mg by subcutaneous injection (SC) at week 12 and then every 4 weeks (Q4W) for 40 weeks, ustekinumab approximately 6 mg/kg by IV administration at week 0 followed by 90 mg SC administration every 8 weeks (Q8W) starting at week 8, or placebo. Patients randomised to placebo at baseline who achieved clinical response by Patient-Reported Outcome (PRO) at week 12 (defined as at least a 30% decrease in stool frequency (SF) and/or abdominal pain (AP) with neither score worse than baseline) remained on placebo. Patients randomized to placebo at baseline who did not achieve clinical response by PRO at week 12 received mirikizumab 900 mg by IV infusion at week 12, week 16, and week 20 followed by a maintenance dose of 300 mg Q4W SC at week 24 through week 48.

Disease activity at baseline was assessed by (1) the unweighted daily average of SF (2), the unweighted daily average AP (ranging from 0 to 3) and (3) Simple Endoscopic Score for Crohn's disease (SES-CD) (ranging from 0 to 56).

Moderately to severely active CD was defined by SF \geq 4 and/or AP \geq 2 and SES-CD \geq 7 (centrally read) for patients with ileal-colonic and isolated colonic disease or \geq 4 for patients with isolated ileal disease. At baseline patients had a median SF of 6, AP of 2 and SES-CD of 12.

Patients had a mean age of 36 years (range 18 to 76 years); 45 % were female; and 72 % identified as White, 25 % as Asian, 2 % as Black, and 1 % as another racial group. Patients were permitted to use stable doses of corticosteroids, immunomodulators (e.g., 6-mercatopurine, azathioprine or methotrexate) and/or aminosalicylates. At baseline, 31 % of patients were receiving oral corticosteroids, 27 % were receiving immunomodulators, and 44 % were receiving aminosalicylates.

At baseline, 49 % had a loss of response, inadequate response, or intolerance to one or more biologic therapy (prior biologic failure); 46 % of patients had failed TNF α inhibitors and 11 % had failed vedolizumab therapy.

The co-primary endpoints of VIVID-1 were (1) clinical response by PRO at week 12 and endoscopic response at week 52 versus placebo and (2) clinical response by PRO at week 12 and clinical remission by Crohn's Disease Activity Index (CDAI) at week 52; the results for the co-primary endpoints and the major secondary endpoints at week 52 versus placebo are provided in table 4. The major secondary endpoints at week 12 versus placebo are provided in table 5.

| | Placebo n=199 | | Mirikizumab 300 mg SC | | Treatment |
|--|---------------------|---------|--------------------------|----------------|--------------------------------|
| | | | | | Difference from |
| | | | injectio | n ^a | Placebo^b |
| | | | n=579 |) | (99.5% CI) |
| | n | % | n | % | |
| Co- | orimary en | dpoints | | | |
| Clinical response by PRO ^c at week 12 and | 18/199 | 9 % | 220/579 | 38 % | 29% ^e (21 %, 37 %) |
| endoscopic response ^d at week 52 | | | | | |
| Without prior biologic failure | 12/102 | 12 % | 117/298 | 39 % | |
| Prior biologic failure ^f | 6/97 | 6 % | 103/281 | 37 % | |
| Clinical response by PRO ^c at week 12 and | 39/199 | 20 % | 263/579 | 45 % | 26 % ^e (16 %, 36 %) |
| clinical remission by CDAI ^g at week 52 | | | | | |
| Without prior biologic failure | 27/102 | 27 % | 141/298 | 47 % | |
| Prior biologic failure ^f | 12/97 | 12 % | 122/281 | 43 % | |
| Add | ditional en | dpoints | | | |
| Endoscopic response ^d at week 52 | 18/199 ^h | 9 % | 280/579 | 48 % | 39 % ^e (31 %, 47 %) |
| Without prior biologic failure | $12/102^{h}$ | 12 % | 154/298 | 52 % | |
| Prior biologic failure ^f | 6/97 ^h | 6 % | 126/281 | 45 % | |
| Clinical remission by CDAI ^h at week 52 | 39/199 ^h | 20 % | 313/579 | 54 % | 35 % ^e (25 %, 44 %) |
| Without prior biologic failure | $27/102^{h}$ | 27 % | 169/298 | 57 % | |
| Prior biologic failure ^f | 12/97 ^h | 12 % | 144/281 | 51 % | |
| Clinical response by PRO ^c at week 12 and | 39/199 | 20 % | 263/579 | 45 % | 26 % ^e (16 %, 36 %) |
| clinical remission by PRO ⁱ at week 52 | | | | | |
| Clinical response by PRO ^c at week 12 and | 8/199 | 4 % | 136/579 | 24 % | 19 % ^e (13 %, 26 %) |
| endoscopic remission ^j at week 52 | | | | | |
| Clinical response by PRO ^c at week 12 and | 37/199 | 19 % | 253/579 | 44 % | 25 % ^e (15 %, 35 %) |
| corticosteroid-free clinical remission by | | | | | |
| CDAI ^{g, k} at Week 52 | | | | | |

| Table 4. Proportion of patients with Cro | ohn's disease meeting | gefficacy endpoints in | VIVID-1 at |
|--|-----------------------|------------------------|------------|
| week 52 | | | |

Abbreviations: AP = abdominal pain; CDAI = Crohn's Disease Activity Index; CI = confidence interval; PRO = 2 of the patient-reported items of the CDAI (SF and AP); SES-CD = Simple Endoscopic Score for Crohn's Disease; SF = stool frequency.

- a Following mirikizumab 900 mg as an IV infusion at week 0, week 4, and week 8 patients received mirikizumab 300 mg as a SC injection at week 12 and every 4 weeks thereafter for up to an additional 40 weeks.
- b For binary endpoints adjusted treatment difference was based on Cochran-Mantel-Haenszel method adjusted for baseline covariates.
- c Clinical response by PRO is defined as at least a 30% decrease in SF and/or AP and neither score worse than baseline.
- d Endoscopic response is defined as ≥50% reduction from baseline in SES-CD total score, based on central reading.
- e p < 0.000001
- f Prior biologic failure includes loss of response, inadequate response, or intolerance to one or more biologic therapy (e.g. $TNF\alpha$ antagonist or integrin receptor antagonist).
- g Clinical remission by CDAI is defined as CDAI total score < 150.
- h Placebo sample size includes all patients randomized to placebo at baseline. Placebo patients that did not achieve clinical response by PRO at week 12 were considered non-responders at week 52.
- i Clinical remission by PRO is defined as SF ≤ 3 and not worse than baseline (according to the Bristol Stool Scale Category 6 or 7) and AP ≤ 1 and not worse than baseline.
- j Endoscopic remission is defined as SES-CD Total Score ≤ 4 and at least a 2-point reduction versus baseline and no subscore >1 in any individual variable, based on central reading.
- k Corticosteroid-free is defined as patients who were corticosteroid-free from week 40 to week 52.
Bowel urgency remission

Bowel urgency remission was assessed during VIVID-1 with an urgency numeric rating scale (NRS) of 0 to 10. A greater proportion of patients with a baseline urgency NRS weekly average score \geq 3 treated with mirikizumab compared to placebo achieved clinical response by PRO at week 12 and an urgency NRS weekly average score of \leq 2 at week 52 (33 % versus 11 %).

Table 5. Proportion of patients with Crohn's disease meeting efficacy endpoints in VIVID -1 at week 12

| Endpoint | Placebo n=199 | | Mirikizumab 900 mg IV infusion ^a n=579 | | Treatment Difference from Placebo ^b (99.5% CI) |
|--|------------------|------|--|------|--|
| | n | % | n | % | |
| Clinical response by PRO ^c | 103/199 | 52 % | 409/579 | 71 % | 19 % ^e (8 %, 30 %) |
| Clinical remission by CDAI ^g | 50/199 | 25 % | 218/579 | 38 % | 12 % ^h (2 %, 23 %) |
| Endoscopic response ^d | 25/199 | 13 % | 188/579 | 32 % | 20 % ^e (11 %, 28 %) |
| Endoscopic remission ^j | 14/199 | 7 % | 102/579 | 18 % | 11 % ^h (4 %, 17 %) |
| Change from baseline in FACIT-fatigue ^h | LS Mean | SE | LS Mean | SE | |
| | 2.6 | 0.61 | 5.9 | 0.36 | $3.2^{\rm f}(1.2, 5.2)$ |

Abbreviations: FACIT-fatigue = Functional Assessment of Chronic Illness Therapy – fatigue;

LS Mean = Least Square Mean; SE = Standard Error; others see above table 4.

- a Weeks 0, 4, 8
- b see table 4. Also see footnote k.
- c, d, e, g, j see table 4
- f p-value < 0.005
- h For change from baseline in FACIT-fatigue, the LS means and treatment difference were based on ANCOVA model adjusted for baseline FACIT-fatigue and other covariates. At baseline, mean FACIT-fatigue values were similar across treatment groups and ranged from 32.3-31.5.

Improvements in clinical remission by CDAI were observed as early as week 4 in a greater proportion of patients treated with mirikizumab compared to placebo.

Reductions in abdominal pain were observed as early as week 4 and in stool frequency as early as week 6 in patients treated with mirikizumab compared to placebo.

The efficacy and safety profile of mirikizumab was consistent across subgroups, i.e. age, gender, body weight, disease activity severity at baseline and region. The effect size may vary.

Active comparator arm

At week 52, mirikizumab demonstrated non-inferiority (pre-specified margin of -10%) to ustekinumab on clinical remission by CDAI (mirikizumab 54 %; ustekinumab 48 %). Superiority over ustekinumab in week 52 endoscopic response was not achieved (mirikizumab 48 %, ustekinumab 46 %).

Histologic outcome

Across all five intestinal segments 44 % of patients on mirikizumab achieved-the composite endpoint of clinical response by PRO at week 12 and histologic response at week 52 compared to 16 % of patients on placebo. Histologic response at week 52 was achieved by 58 % of patients compared to 49% on ustekinumab.

Health-related quality of life

At week 12, change in the Inflammatory Bowel Disease Questionnaire (IBDQ) score was 36.9 for mirikizumab and 17.4 for placebo; IBDQ response and remission were achieved in 69 % and 52 %

of mirikizumab-treated patients versus 45 % and 28 % in placebo patients respectively. These improvements were maintained at week 52.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Omvoh in one or more subsets of the paediatric population in the treatment of ulcerative colitis and Crohn's disease (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

There was no apparent accumulation in serum mirikizumab concentration over time when given subcutaneously every 4 weeks.

Exposure

Ulcerative colitis

Mean (coefficient of variation in %) C_{max} and area under the curve (AUC) after induction dosing (300 mg every 4 weeks administered by intravenous infusion) in patients with ulcerative colitis were 99.7 µg/mL (22.7 %) and 538 µg*day/mL (34.4 %), respectively. The mean (CV %) C_{max} and AUC after maintenance dosing (200 mg every 4 weeks by subcutaneous injection) were 10.1 µg/mL (52.1 %) and 160 µg*day/mL (57.6 %), respectively.

Crohn's disease

Mean (coefficient of variation in %) C_{max} and area under the curve (AUC) after induction dosing (900 mg every 4 weeks administered by intravenous infusion) in patients with Crohn's disease were 332 µg/mL (20.6 %) and 1820 µg*day/mL (38.1 %), respectively. The mean (CV %) C_{max} and AUC after maintenance dosing (300 mg every 4 weeks by subcutaneous injection) were 13.6 µg/mL (48.1 %) and 220 µg*day/mL (55.9 %), respectively.

Absorption

Following subcutaneous dosing of mirikizumab for ulcerative colitis, median (range) Tmax was 5 (3.08-6.75) days post dose and geometric mean (CV%) absolute bioavailability of 44 % (34 %). Following subcutaneous dosing of mirikizumab for Crohn's disease, median (range) Tmax was 5 (3 to 6.83) days post dose and geometric mean (CV%) absolute bioavailability was 36.3% (31%).

Injection site location did not significantly influence absorption of mirikizumab.

Distribution

The geometric mean total volume of distribution was 4.83 L (21%) in patients with ulcerative colitis and 4.40 L (14%) in patients with Crohn's disease.

Biotransformation

Mirikizumab is a humanised IgG4 monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgGs.

Elimination

In the population PK analysis, geometric mean (CV %) clearance was 0.0229 L/hr (34 %) and the geometric mean half-life is approximately 9.3 days (40 %) in patients with ulcerative colitis. The geometric mean (CV%) clearance was 0.0202 L/hr (38 %) and the geometric mean (CV %) half-life

is also approximately 9.3 days (26 %) in patients with Crohn's disease. Clearance is independent of dose.

Dose proportionality

Mirikizumab exhibited linear pharmacokinetics with dose-proportional increase in exposure over a dose range of 5 to 2 400 mg given as an intravenous infusion or over a dose range of 120 to 400 mg given as a subcutaneous injection in patients with ulcerative colitis or Crohn's disease or in healthy volunteers.

Special populations

Population pharmacokinetic analysis showed that age, sex, weight, or race/ethnicity did not have a clinically meaningful effect on the pharmacokinetics of mirikizumab (see also section 4.8, "immunogenicity"). Among the 1 362 subjects with ulcerative colitis exposed to mirikizumab in Phase 2 and Phase 3 studies, 99 (7.3 %) patients were 65 years or older and 11 (0.8 %) patients were 75 years or older.

Renal or hepatic impairment

Specific clinical pharmacology studies to evaluate the effects of renal impairment and hepatic impairment on the pharmacokinetics of mirikizumab have not been conducted.

In patients with ulcerative colitis, population pharmacokinetic analysis showed that creatinine clearance (range of 36.2 to 291 mL/min) or total bilirubin (range of 1.5 to 29 μ mol/L) did not affect mirikizumab pharmacokinetics.

In patients with Crohn's disease, population pharmacokinetic analysis showed that creatinine clearance (range of 26.5 to 269 mL/min) or total bilirubin (range of 1.5 to 36 μ mol/L) did not affect mirikizumab pharmacokinetics.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction and development.

Carcinogenesis / mutagenesis

Non-clinical studies have not been conducted to evaluate the carcinogenic or mutagenic potential of mirikizumab.

Impairment of fertility

No reproductive organ weight or histopathology effects were observed in sexually mature cynomolgus monkeys that received mirikizumab once weekly for 26 weeks, at a dose of 100 mg/kg (at least 20 times the human maintenance dose).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Histidine Histidine monohydrochloride Sodium chloride Mannitol (E 421) Polysorbate 80 (E 433) Water for injections

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store in a refrigerator (2 °C - 8 °C). Do not freeze. Store in the original package in order to protect from light.

Omvoh may be stored unrefrigerated for up to 2 weeks at a temperature not above 30 °C. If these conditions are exceeded, Omvoh must be discarded.

6.5 Nature and contents of container

Packs for the treatment of ulcerative colitis

Omvoh 100 mg solution for injection in pre-filled syringe

1 mL solution in a type I clear glass syringe.

The syringe is encased in a disposable, single-dose syringe with bromobutyl rubber plunger.

Pack sizes:

- packs of 2 pre-filled syringes
- multipacks containing 6 (3 packs of 2) pre-filled syringes.

Not all pack sizes may be marketed.

Omvoh 100 mg solution for injection in pre-filled pen

1 mL solution in a type I clear glass syringe. The syringe is encased in a disposable, single-dose pen with bromobutyl rubber plunger.

Pack sizes:

- packs of 2 pre-filled pens
- multipacks containing 4 (2 packs of 2) pre-filled pens
- multipacks containing 6 (3 packs of 2) pre-filled pens.

Not all pack sizes may be marketed.

Packs for the treatment of Crohn's disease:

<u>Omvoh 100 mg solution for injection in pre-filled syringe and Omvoh 200 mg solution for injection</u> <u>in pre-filled syringe</u>

Pre-filled syringes with 1 mL and 2 mL solution in a type I clear glass syringe. Each syringe is encased in a disposable, single-dose syringe with bromobutyl rubber plunger. Pack sizes:

- Packs of 2 pre-filled syringes (1 pre-filled syringe of 100 mg and 1 pre-filled syringe of 200 mg)
- Multipacks containing 6 pre-filled syringes (3 packs of 1 pre-filled syringe of 100 mg and 1 pre-filled syringe of 200 mg each).

Not all pack sizes may be marketed.

<u>Omvoh 100 mg solution for injection in pre-filled pen and 200 mg solution for injection in pre-filled</u> <u>pen</u>

Pre-filled pens with 1 mL and 2 mL solution in a type I clear glass syringe. Each syringe is encased in a disposable, single-dose pen with bromobutyl rubber plunger.

Pack sizes:

- Packs of 2 pre-filled pens (1 pre-filled pen of 100 mg and 1 pre-filled pen of 200 mg)
- Multipacks containing 6 pre-filled pens (3 packs of 1 pre-filled pen of 100 mg and 1 pre-filled pen of 200 mg each).

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

For single use only. Omvoh should not be used if particles appear or if the solution is cloudy and/or distinctly brown.

Do not use Omvoh that has been frozen.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands.

8. MARKETING AUTHORISATION NUMBERS

Omvoh 100 mg solution for injection in pre-filled syringe

EU/1/23/1736/002 EU/1/23/1736/003

Omvoh 100 mg solution for injection in pre-filled pen

EU/1/23/1736/004 EU/1/23/1736/005 EU/1/23/1736/006

Omvoh 100 mg solution for injection in pre-filled syringe and Omvoh 200 mg solution for injection in pre-filled syringe

EU/1/23/1736/007 EU/1/23/1736/008

Omvoh 100 mg solution for injection in pre-filled pen and Omvoh 200 mg solution for injection in pre-filled pen

EU/1/23/1736/009 EU/1/23/1736/010

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 26 May 2023

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <u>https://www.ema.europa.eu</u>.

ANNEX II

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
- **B.** CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork, Ireland

Name and address of the manufacturer responsible for batch release

Pre-filled pen, Pre-filled syringe, Vial (1 pack) Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, France

Vial (3 pack) Lilly S.A., Avda. de la Industria Nº 30, 28108 Alcobendas, Madrid, Spain

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

OUTER CARTON - VIAL

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 300 mg concentrate for solution for infusion mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 300 mg of mirikizumab in 15 mL (20 mg/mL).

3. LIST OF EXCIPIENTS

Excipients: sodium citrate dihydrate (E 331); citric acid, anhydrous (E 330); sodium chloride; polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion 300 mg/15 mL 1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after dilution. For single use only. Do not shake. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Keep the vial in the outer carton in order to protect from light

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN

NN

OUTER CARTON FOR VIAL MULTIPACK (with Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 300 mg concentrate for solution for infusion mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 300 mg of mirikizumab in 15 mL (20 mg/mL).

3. LIST OF EXCIPIENTS

Excipients: sodium citrate dihydrate (E 331); citric acid, anhydrous (E 330); sodium chloride; polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion 300 mg/15 mL Multipack: 3 (3 packs of 1) vials

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after dilution. For single use only. Do not shake. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Keep the vial in the outer carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/011

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN NN

NN

INTERMEDIATE CARTON OF VIAL MULTIPACK (without Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 300 mg concentrate for solution for infusion mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 300 mg of mirikizumab in 15 mL (20 mg/mL).

3. LIST OF EXCIPIENTS

Excipients: sodium citrate dihydrate (E 331); citric acid, anhydrous (E 330); sodium chloride; polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion

300 mg/15 mL

1 vial. Component of a multipack, can't be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after dilution. For single use only. Do not shake. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Keep the vial in the outer carton in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/011

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Omvoh 300 mg sterile concentrate mirikizumab For IV use after dilution

2. METHOD OF ADMINISTRATION

Read the package leaflet before use.

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

300 mg/15 mL

6. OTHER

OUTER CARTON - PRE-FILLED SYRINGE (pack of 2)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg solution for injection in pre-filled syringe mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 100 mg of mirikizumab in 1 mL solution.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection 2 pre-filled syringes of 100 mg



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN

NN

OUTER CARTON FOR MULTIPACK (with Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg solution for injection in pre-filled syringe mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 100 mg of mirikizumab in 1 mL solution.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection Multipack: 6 (3 packs of 2) pre-filled syringes.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC SN

INTERMEDIATE CARTON OF MULTIPACK (without Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg solution for injection in pre-filled syringe mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe contains 100 mg of mirikizumab in 1 mL solution.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

2 pre-filled syringes of 100 mg. Component of a multipack, can't be sold separately.



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PRE-FILLED SYRINGE LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Omvoh 100 mg injection mirikizumab SC

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. **BATCH NUMBER**

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mL

6. OTHER

OUTER CARTON - PRE-FILLED SYRINGE (pack of 2)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg Omvoh 200 mg solution for injection in pre-filled syringe mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe of 1 mL solution contains 100 mg of mirikizumab. Each pre-filled syringe of 2 mL solution contains 200 mg of mirikizumab.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421), polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection 1 pre-filled syringe of 100 mg and 1 pre-filled syringe of 200 mg



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/007

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg Omvoh 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC SN

OUTER CARTON FOR MULTIPACK (with Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg Omvoh 200 mg solution for injection in pre-filled syringe mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe of 1 mL solution contains 100 mg of mirikizumab. Each pre-filled syringe of 2 mL solution contains 200 mg of mirikizumab.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

Multipack: 6 pre-filled syringes (3 packs each containing 1 pre-filled syringe of 100 mg and 1 pre-filled syringe of 200 mg)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/008

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg Omvoh 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN

NN

INTERMEDIATE CARTON OF MULTIPACK (without Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg Omvoh 200 mg solution for injection in pre-filled syringe mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled syringe of 1 mL solution contains 100 mg of mirikizumab. Each pre-filled syringe of 2 mL solution contains 200 mg of mirikizumab.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection 1 pre-filled syringe of 100 mg and 1 pre-filled syringe of 200 mg. Component of a multipack, can't be sold separately.



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/008

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg Omvoh 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PRE-FILLED SYRINGE LABEL 100 mg

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Omvoh 100 mg injection mirikizumab SC

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. **BATCH NUMBER**

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mL

6. OTHER

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PRE-FILLED SYRINGE LABEL 200 mg

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Omvoh 200 mg injection mirikizumab SC

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. **BATCH NUMBER**

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

 $2\,\text{mL}$

6. OTHER

OUTER CARTON - PRE-FILLED PEN (pack of 2)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg solution for injection in pre-filled pen mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen contains 100 mg of mirikizumab in 1 mL solution.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection 2 pre-filled pens of 100 mg



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/004

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN

NN

OUTER CARTON OF MULTIPACK (with Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg solution for injection in pre-filled pen mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen contains 100 mg of mirikizumab in 1 mL solution.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection Multipack: 4 (2 packs of 2) pre-filled pens of 100 mg Multipack: 6 (3 packs of 2) pre-filled pens of 100 mg

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/005 (4 pre-filled pens) EU/1/23/1736/006 (6 pre-filled pens)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN

NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

INTERMEDIATE CARTON OF MULTIPACK (without Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg solution for injection in pre-filled pen mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen contains 100 mg of mirikizumab in 1 mL solution.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

2 pre-filled pens of 100 mg. Component of a multipack, can't be sold separately.



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/005 (4 pre-filled pens) EU/1/23/1736/006 (6 pre-filled pens)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PRE-FILLED PEN LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Omvoh 100 mg solution for injection mirikizumab Subcutaneous use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. **BATCH NUMBER**

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mL

6. OTHER

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON - PRE-FILLED PEN (pack of 2)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg Omvoh 200 mg solution for injection in pre-filled pen mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen of 1 mL solution contains 100 mg of mirikizumab. Each pre-filled pen of 2 mL solution contains 200 mg of mirikizumab.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

1 pre-filled pen of 100 mg and 1 pre-filled pen of 200 mg



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/009

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg Omvoh 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC SN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (with Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg Omvoh 200 mg solution for injection in pre-filled pen mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen of 1 mL solution contains 100 mg of mirikizumab. Each pre-filled pen of 2 mL solution contains 200 mg of mirikizumab.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

Multipack: 3 packs each containing 1 pre-filled pen of 100 mg and 1 pre-filled pen of 200 mg

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/010

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg Omvoh 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN

NN

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

INTERMEDIATE CARTON OF MULTIPACK (without Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Omvoh 100 mg Omvoh 200 mg solution for injection in pre-filled pen mirikizumab

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each pre-filled pen of 1 mL solution contains 100 mg of mirikizumab. Each pre-filled pen of 2 mL solution contains 200 mg of mirikizumab.

3. LIST OF EXCIPIENTS

Excipients: histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection 1 pre-filled pen of 100 mg and 1 pre-filled pen of 200 mg. Component of a multipack, can't be sold separately.



5. METHOD AND ROUTE(S) OF ADMINISTRATION

For single use only. Read the package leaflet before use. Subcutaneous use. Do not shake.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. Do not freeze. Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/23/1736/010

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Omvoh 100 mg Omvoh 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PRE-FILLED PEN LABEL 100 mg

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Omvoh 100 mg solution for injection mirikizumab Subcutaneous use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. **BATCH NUMBER**

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mL

6. OTHER

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PRE-FILLED PEN LABEL 200 mg

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Omvoh 200 mg solution for injection mirikizumab Subcutaneous use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. **BATCH NUMBER**

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

 $2 \, mL$

6. OTHER

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

Omvoh 300 mg concentrate for solution for infusion mirikizumab

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

- 1. What Omvoh is and what it is used for
- 2. What you need to know before you receive Omvoh
- 3. How Omvoh is used
- 4. Possible side effects
- 5. How to store Omvoh
- 6. Contents of the pack and other information

1. What Omvoh is and what it is used for

Omvoh is used to treat the following inflammatory bowel diseases:

- Ulcerative colitis
- Crohn's disease

Omvoh contains the active substance mirikizumab, a monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind specifically to certain target proteins in the body. Omvoh works by attaching to and blocking a protein in the body called IL-23 (interleukin-23), which is involved in inflammation. By blocking the action of IL-23, Omvoh reduces inflammation and other symptoms associated with ulcerative colitis and Crohn's disease.

Ulcerative colitis

Ulcerative colitis is a chronic inflammatory disease of the large bowel. If you have ulcerative colitis, you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Omvoh to reduce signs and symptoms of ulcerative colitis such as diarrhoea, abdominal pain, urgency and rectal bleeding.

Crohn's disease

Crohn's disease is a chronic inflammatory disease of the digestive tract. If you have active Crohn's disease, you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Omvoh to reduce signs and symptoms of Crohn's disease such as diarrhoea, abdominal pain, fatigue and urgency.

2. What you need to know before you receive Omvoh

Do not use Omvoh

- if you are allergic to mirikizumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Omvoh.
- If you have important active infections (active tuberculosis).

Warnings and precautions

- Talk to your doctor or pharmacist before using this medicine. •
- Your doctor will check how well you are before treatment.
- Make sure you tell your doctor about any illness you have before treatment. •

Infections

- Omvoh can potentially cause serious infections.
- Treatment with Omvoh should not be started if you have an active infection until the infection is ٠ gone.
- After starting the treatment, tell your doctor right away if you have any symptoms of an infection such as:
 - o shortness of breath o fever o chills o runny nose \circ muscle aches \circ sore throat
 - o cough

- pain during urination
- Also tell your doctor if you have recently been near anyone who might have tuberculosis. •
- Your doctor will examine you and may do a test for tuberculosis before you have Omvoh. •
- If your doctor thinks you are at risk of an active tuberculosis, you may be given medicines to treat • it.

Vaccinations

Your doctor will check to see if you need any vaccinations before starting treatment. Tell your doctor, pharmacist or nurse if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Allergic reactions

- Omvoh can potentially cause serious allergic reactions.
- Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
 - low blood pressure
 - o fainting
- swelling of the face, lips, mouth, tongue
- o dizziness

o rash

or throat, trouble breathing 0

sensation of throat tightening or chest tightness.

Liver blood test

Your doctor will conduct blood tests before starting and during treatment with Omvoh to check if your liver is functioning normally. If blood tests are abnormal, your doctor might interrupt therapy with Omvoh and do additional tests on your liver to determine the cause.

Children and adolescents

Omvoh is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Omvoh

Tell your doctor, pharmacist or nurse

- if you are using, have recently used or might use any other medicines.
- if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Omvoh in pregnancy. The effects of Omvoh in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and should use effective contraception while using Omvoh and for at least 10 weeks after the last Omvoh dose.

If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.

Driving and using machines

Omvoh is unlikely to influence your ability to drive and use machines.

Omvoh contains sodium

This medicine contains 60 mg sodium (main component of cooking/table salt) in each 300 mg dose for the treatment of ulcerative colitis. This is equivalent to 3 % of the recommended maximum daily dietary intake of sodium for an adult.

This medicine contains 180 mg sodium (main component of cooking/table salt) in each 900 mg dose for the treatment of Crohn's disease. This is equivalent to 9 % of the recommended maximum daily dietary intake of sodium for an adult.

Before Omvoh is given to you, it is mixed with a solution that might contain sodium. Talk to your doctor if you are on a low salt diet.

Omvoh contains polysorbate

This medicine contains 0.5 mg/mL of polysorbate 80 in each vial which is equivalent to 7.5 mg for the induction dose to treat ulcerative colitis and equivalent to 22.5 mg for the induction dose to treat Crohn's disease. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How Omvoh is used

Omvoh is intended for use under the guidance and supervision of a doctor experienced in the diagnosis and treatment of ulcerative colitis and Crohn's disease.

How much Omvoh is given and for how long

Your doctor will decide how much Omvoh you need and for how long. Omvoh is for long-term treatment. Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect.

Ulcerative colitis

• Treatment start: The first dose of Omvoh is 300 mg and will be given by your doctor by intravenous infusion (drip in a vein in your arm) over at least 30 minutes. After the first dose, you will receive another dose of Omvoh 300 mg 4 weeks later and again after an additional 4 weeks.

If you do not have adequate therapeutic response after these 3 infusions, your doctor might consider continuing intravenous infusions at weeks 12, 16 and 20.

• Maintenance therapy: 4 weeks after the last intravenous infusion, a maintenance dose of Omvoh 200 mg will be given by an injection under the skin ('subcutaneously') and then every

4 weeks. The maintenance dose of 200 mg will be given by using 2 injections each containing 100 mg of Omvoh.

If you lose response after receiving the maintenance dose of Omvoh, your doctor may decide to give you 3 doses of Omvoh by intravenous infusions.

Your doctor or nurse will tell you when to switch to subcutaneous injections.

During maintenance therapy you and your doctor or nurse should decide if you should inject Omvoh yourself after training in subcutaneous injection technique. It is important not to try to inject yourself until you have been trained by your doctor or nurse. Your doctor or nurse will offer the necessary training.

Crohn's disease

- Treatment start: The first dose of Omvoh is 900 mg (3 vials with 300 mg each) and will be given by your doctor by intravenous infusion (drip in a vein in your arm) over at least 90 minutes. After the first dose, you will receive another dose of Omvoh 900 mg 4 weeks later and again after an additional 4 weeks.
- Maintenance therapy: 4 weeks after the last intravenous infusion, a maintenance dose of Omvoh 300 mg will be given by an injection under the skin ('subcutaneously') and then every 4 weeks. The maintenance dose of 300 mg will be given by one pre-filled syringe or pen of 100 mg and one pre-filled syringe or pen of 200 mg. The injections may be administered in any order.

The 200 mg pre-filled syringe or pen is only for treatment of Crohn's disease.

Your doctor or nurse will tell you when to switch to subcutaneous injections.

During maintenance therapy you and your doctor or nurse should decide if you should inject Omvoh yourself after training in subcutaneous injection technique. It is important not to try to inject yourself until you have been trained by your doctor or nurse. Your doctor or nurse will offer the necessary training.

If you receive more Omvoh than you should

If you have received more Omvoh than you should or the dose has been given sooner than prescribed, inform your doctor.

If you forget to use Omvoh

If you missed a dose of Omvoh, talk to your doctor.

If you stop using Omvoh

You should not stop using Omvoh without speaking to your doctor first. If you stop treatment, symptoms of your disease may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common (may affect more than 1 in 10 people)

- Injection site reactions (e.g. red skin, pain)

Common (may affect up to 1 in 10 people)

- Upper respiratory tract infections (nose and throat infections)
- Joint pain
- Headache
- Rash

Uncommon (may affect up to 1 in 100 people)

- Shingles
- Infusion-related allergic reaction (e.g. itch, hives)
- Increase in the level of liver enzymes in your blood

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in <u>Appendix V</u>. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Omvoh

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial label and on the outer carton after "EXP". The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C). Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Do not use this medicine if you notice that the vial is damaged, or the medicine is cloudy, distinctly brown, or has particles in it.

This medicine is for single use only.

Do not throw away any medicines via wastewater. Ask your doctor, nurse or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Diluted solution

It is recommended to start the infusion immediately after dilution. If not immediately used, the diluted solution prepared with sodium chloride 9 mg/mL (0.9 %) solution for injection may be stored refrigerated (2 °C – 8 °C) for not more than 96 hours or at room temperature not exceeding 25 °C for not more than 10 hours (total time must not exceed 96 hours) starting from the time of vial puncture. The diluted infusion solution prepared with 5 % glucose must be used within 48 hours, of which not more than 5 hours are permitted at nonrefrigerated temperature not to exceed 25 °C, starting at the time of vial puncture.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Do not dilute the infusion solution with other solutions or co-infuse with other electrolytes or medications.

Keep the diluted solution away from direct heat or light. Do not freeze the diluted solution.

6. Contents of the pack and other information

What Omvoh contains

- The active substance is mirikizumab. Each vial contains 300 mg mirikizumab in 15 mL (20 mg/mL). - The other ingredients are sodium citrate dihydrate (E 331); citric acid, anhydrous (E 330); sodium chloride; polysorbate 80 (E 433); water for injections.

What Omvoh looks like and contents of the pack

Omvoh is a solution in a clear glass vial. Its colour may vary from colourless to slightly yellow.

Pack sizes of 1 vial and 3 vials. Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands

Manufacturer

Lilly France S.A.S. Rue du Colonel Lilly 67640 Fegersheim France

Lilly S.A. Avda. de la Industria Nº 30 28108 Alcobendas, Madrid Spain

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgique/België/Belgien Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

България ТП "Ели Лили Недерланд" Б.В. - България тел. + 359 2 491 41 40

Česká republika ELI LILLY ČR, s.r.o. Tel: + 420 234 664 111

Danmark Eli Lilly Danmark A/S Tlf.: +45 45 26 60 00

Deutschland Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222

Eesti Eli Lilly Nederland B.V. Tel: +372 6 817 280

Ελλάδα ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: +30 210 629 4600 Lietuva Eli Lilly Lietuva Tel. +370 (5) 2649600

Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

Magyarország Lilly Hungária Kft. Tel: + 36 1 328 5100

Malta Charles de Giorgio Ltd. Tel: + 356 25600 500

Nederland Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800

Norge Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00

Österreich Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780 **España** Lilly S.A. Tel: + 34-91 663 50 00

France Lilly France Tél: +33-(0) 1 55 49 34 34

Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999

Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377

Ísland Icepharma hf. Sími + 354 540 8000

Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42571

Κύπρος Phadisco Ltd Τηλ: +357 22 715000

Latvija Eli Lilly (Suisse) S.A. Pārstāvniecība Latvijā Tel: +371 67364000

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: <u>https://www.ema.europa.eu</u>.

-----¥-----¥

Omvoh 300 mg concentrate for solution for infusion mirikizumab

The following information is intended for healthcare professionals only:

Do not use Omvoh that has been frozen.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00

Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600

România Eli Lilly România S.R.L. Tel: + 40 21 4023000

Slovenija Eli Lilly farmacevtska družba, d.o.o. Tel: +386 (0)1 580 00 10

Slovenská republika Eli Lilly Slovakia, s.r.o. Tel: + 421 220 663 111

Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358-(0) 9 85 45 250

Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800 Dilution prior to intravenous infusion

- 1. Each vial is for single use only.
- 2. Prepare the infusion solution using aseptic technique to ensure the sterility of the prepared solution.
- 3. Inspect the content of the vial. The concentrate should be clear, colourless to slightly yellow and free of visible particles. Otherwise, it should be discarded.
- 4. Prepare the infusion bag for treatment of either ulcerative colitis or Crohn's disease as specified below. Note that there are unique instructions and volumes specified for each indication.

Ulcerative colitis: one 15 mL vial (300 mg)

Withdraw 15 mL of the mirikizumab vial (300 mg) using an appropriately sized needle (18 to 21 gauge is recommended) and transfer to the infusion bag. If administered for the treatment of ulcerative colitis, the concentrate should be diluted only in infusion bags (bag size ranging from 50-250 mL) containing either sodium chloride 9 mg/mL (0.9 %) solution for injection or 5% glucose solution for injection. The final concentration after dilution is approximately 1.1 mg/mL to approximately 4.6 mg/mL.

Crohn's disease: three 15 mL vials; total volume = 45 mL (900 mg)

First, withdraw and discard 45 mL of diluent from the infusion bag. Next, withdraw 15 mL from each of the three mirikizumab vials (900 mg) and transfer to the infusion bag, using an appropriately sized syringe and needle (18 to 21 gauge is recommended). If administered for the treatment of Crohn's disease, the concentrate should be diluted only in infusion bags (bag size ranging from 100-250 mL) containing either sodium chloride 9 mg/mL (0.9 %) solution for injection or 5 % glucose solution for injection.

The final concentration after dilution is approximately 3.6 mg/mL to approximately 9 mg/mL.

5. Gently invert the infusion bag to mix. Do not shake the prepared bag.

Administration of the diluted solution

- 6. The intravenous administration set (infusion line) should be connected to the prepared intravenous bag and the line should be primed.
 For ulcerative colitis, the infusion should be administered for at least 30 minutes.
 For Crohn's disease, the infusion should be administered for at least 90 minutes.
- 7. At the end of the infusion, to ensure a full dose is administered, the infusion line should be flushed with sodium chloride 9 mg/mL (0.9 %) solution or 5 % glucose solution for injection. The flush should be administered at the same rate as used for Omvoh administration. The time required to flush Omvoh solution from the infusion line is in addition to the minimum 30 minutes (ulcerative colitis) or 90 minutes (Crohn's disease) infusion time.

Package leaflet: Information for the patient

Omvoh 100 mg solution for injection in pre-filled syringe

mirikizumab

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

- 1. What Omvoh is and what it is used for
- 2. What you need to know before you use Omvoh
- 3. How to use Omvoh
- 4. Possible side effects
- 5. How to store Omvoh
- 6. Contents of the pack and other information

1. What Omvoh is and what it is used for

Omvoh contains the active substance mirikizumab, a monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind specifically to certain target proteins in the body. Omvoh works by attaching to and blocking a protein in the body called IL-23 (interleukin-23), which is involved in inflammation. By blocking the action of IL-23, Omvoh reduces inflammation and other symptoms associated with ulcerative colitis.

Ulcerative colitis

Ulcerative colitis is a chronic inflammatory disease of the large bowel. If you have ulcerative colitis, you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Omvoh to reduce signs and symptoms of ulcerative colitis such as diarrhoea, abdominal pain, urgency and rectal bleeding.

2. What you need to know before you use Omvoh

Do not use Omvoh

- if you are allergic to mirikizumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Omvoh.
- If you have important active infections (active tuberculosis).

Warnings and precautions

- Talk to your doctor or pharmacist before using this medicine.
- Your doctor will check how well you are before treatment.
- Make sure you tell your doctor about any illness you have before treatment.

Infections

- Omvoh can potentially cause serious infections. Treatment with Omvoh should not be started if you have an active infection until the infection is gone.
- After starting the treatment, tell your doctor right away if you have any symptoms of an infection such as:
 - fever
 chills
 muscle aches
 sore throat
 - cough pain during urination
- Also tell your doctor if you have recently been near anyone who might have tuberculosis.
- Your doctor will examine you and may do a test for tuberculosis before you have Omvoh.
- If your doctor thinks you are at risk of an active tuberculosis, you may be given medicines to treat it.

Vaccinations

Your doctor will check to see if you need any vaccinations before starting treatment. Tell your doctor, pharmacist or nurse if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Allergic reactions

- Omvoh can potentially cause serious allergic reactions.
- Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
 - rash
 fainting
 fainting
 welling of the face, lips, mouth, tongue or throat, trouble breathing
 - dizziness
 sensation of throat tightening or chest tightness.

Liver blood test

Your doctor will conduct blood tests before starting and during treatment with Omvoh to check if your liver is functioning normally. If blood tests are abnormal, your doctor might interrupt therapy with Omvoh and do additional tests on your liver to determine the cause.

Children and adolescents

Omvoh is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Omvoh

Tell your doctor, pharmacist or nurse

- if you are using, have recently used or might use any other medicines.
- if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Omvoh in pregnancy. The effects of Omvoh in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and should use effective contraception while using Omvoh and for at least 10 weeks after the last Omvoh dose.

If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.

Driving and using machines

Omvoh is unlikely to influence your ability to drive and use machines.

Omvoh contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially "sodium -free".

Omvoh contains polysorbate

This medicine contains 0.3 mg/mL of polysorbate 80 in each syringe which is equivalent to 0.6 mg for the maintenance dose to treat ulcerative colitis. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How to use Omvoh

Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor, nurse or pharmacist if you are not sure how to use this medicine.

How much Omvoh is given and for how long

Your doctor will decide how much Omvoh you need and for how long. Omvoh is for long-term treatment. Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect.

Ulcerative colitis

• Treatment start: The first dose of Omvoh is 300 mg and will be given by your doctor by intravenous infusion (drip in a vein in your arm) over at least 30 minutes. After the first dose, you will receive another dose of Omvoh 300 mg 4 weeks later and again after an additional 4 weeks.

If you do not have adequate therapeutic response after these 3 infusions, your doctor might consider continuing intravenous infusions at weeks 12, 16 and 20.

Maintenance therapy: 4 weeks after the last intravenous infusion, a maintenance dose of Omvoh 200 mg will be given by an injection under the skin ('subcutaneously') and then every 4 weeks. The maintenance dose of 200 mg will be given by using 2 injections each containing 100 mg of Omvoh. If you lose response after receiving the maintenance dose of Omvoh, your doctor may decide to give you 3 doses of Omvoh by intravenous infusions.

Your doctor or nurse will tell you when to switch to subcutaneous injections. During maintenance therapy you and your doctor or nurse should decide if you should inject Omvoh yourself after training in subcutaneous injection technique. It is important not to try to inject yourself until you have been trained by your doctor or nurse. Your doctor or nurse will offer the necessary training. A caregiver may also give you your Omvoh injection after proper training. Use a reminder method such as notes in a calendar or diary to help you remember when to take your next dose so that you avoid missing or repeating doses.

If you receive more Omvoh than you should

If you have received more Omvoh than you should or the dose has been given sooner than prescribed, inform your doctor.

If you forget to use Omvoh

If you have forgotten to inject a dose of Omvoh, inject as soon as possible. Thereafter, resume dosing every 4 weeks.

If you stop using Omvoh

You should not stop using Omvoh without speaking to your doctor first. If you stop treatment, symptoms of ulcerative colitis may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common (may affect more than 1 in 10 people)

- Injection site reactions (e.g. red skin, pain)

Common (may affect up to 1 in 10 people):

- Upper respiratory tract infections (nose and throat infections)
- Joint pain
- Headache
- Rash

Uncommon (may affect up to 1 in 100 people):

- Shingles
- Infusion-related allergic reaction (e.g. itch, hives)
- Increase in the level of liver enzymes in your blood.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in <u>Appendix V</u>. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Omvoh

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and on the outer carton after "EXP". The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C). Do not freeze.

Do not microwave the syringes, run hot water over them, or leave them in direct sunlight. **Do not** shake your pre-filled syringe.

Store in the original packaging in order to protect from light. Omvoh may be stored unrefrigerated for up to 2 weeks at a temperature not above 30 °C. If these conditions are exceeded, Omvoh must be discarded.

Do not use this medicine if you notice that the pre-filled syringe is damaged, or the medicine is cloudy, distinctly brown, or has particles in it.

This medicine is for single use only.

Do not throw away any medicines via wastewater. Ask your doctor, nurse or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Omvoh contains

- The active substance is mirikizumab. Each pre-filled syringe contains 100 mg of mirikizumab in 1 mL solution.
- The other ingredients are histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections.

What Omvoh looks like and contents of the pack

Omvoh is a solution in a clear glass cartridge encased in a disposable, single-use syringe. Its colour may vary from colourless to slightly yellow.

Omvoh is available in packs containing 2 pre-filled syringes and in multipacks comprising 3 cartons, each containing 2 pre-filled syringes. Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands

Manufacturer

Lilly France S.A.S. Rue du Colonel Lilly 67640 Fegersheim France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgique/België/Belgien

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

България ТП "Ели Лили Недерланд" Б.В. - България тел. + 359 2 491 41 40

Česká republika ELI LILLY ČR, s.r.o.

Tel: + 420 234 664 111

Danmark Eli Lilly Danmark A/S Tlf.: +45 45 26 60 00

Deutschland Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222

Eesti Eli Lilly Nederland B.V. Tel: +372 6 817 280

Ελλάδα

Lietuva Eli Lilly Lietuva Tel. +370 (5) 2649600

Luxembourg/Luxemburg

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

Magyarország

Lilly Hungária Kft. Tel: + 36 1 328 5100

Malta Charles de Giorgio Ltd. Tel: + 356 25600 500

Nederland

Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800

Norge

Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00

Österreich

 $\Phi APMA\Sigma EPB-\Lambda I\Lambda\Lambda Y A.E.B.E. \\ T\eta\lambda: +30\ 210\ 629\ 4600$

España Lilly S.A. Tel: + 34-91 663 50 00

France Lilly France Tél: +33-(0) 1 55 49 34 34

Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999

Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377

Ísland Icepharma hf. Sími + 354 540 8000

Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42571

Κύπρος Phadisco Ltd Τηλ: +357 22 715000

Latvija Eli Lilly (Suisse) S.A. Pārstāvniecība Latvijā Tel: +371 67364000

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: <u>https://www.ema.europa.eu</u>.

Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780

Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00

Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600

România Eli Lilly România S.R.L. Tel: + 40 21 4023000

Slovenija Eli Lilly farmacevtska družba, d.o.o. Tel: +386 (0)1 580 00 10

Slovenská republika Eli Lilly Slovakia, s.r.o. Tel: + 421 220 663 111

Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358-(0) 9 85 45 250

Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800

Instructions for use

Omvoh 100 mg solution for injection in pre-filled syringe

mirikizumab

2 pre-filled syringes: 1 syringe of 100 mg and 1 syringe of 100 mg



Read this before you inject Omvoh. Follow all the step-by-step instructions.

- 2 Omvoh injections are required for a full dose to treat ulcerative colitis.
- Inject 1 Omvoh pre-filled syringe followed right away by the other Omvoh pre-filled syringe.

Also keep in mind:

- Your healthcare provider should show you how to prepare and inject Omvoh using the pre-filled syringe. **Do not** inject yourself or someone else until you have been shown how to inject Omvoh.
- Each Omvoh pre-filled syringe is for one-time use only. Do not share or reuse your syringe. You may give or get an infection.
- Your healthcare provider may help you decide where on your body to inject your dose. You can also read the "Choose your injection site" section of these instructions to help you choose which area can work best for you.
- If you have vision problems, do not use Omvoh pre-filled syringe without help from a caregiver.
- Keep the Instructions for use and refer to them as needed.

Before you use the Omvoh pre-filled syringes, read and carefully follow all the step-by-step instructions.

Parts of the Omvoh pre-filled syringe



100 mg + 100 mg = 1 Full dose

IMPORTANT:

- 2 injections are required for a full dose to treat ulcerative colitis.
- Inject one syringe followed right away by the other syringe.

Preparing to inject Omvoh

| Take the syringes from the refrigerator | Take 2 syringes from the refrigerator |
|---|---|
| | Leave the needle caps on until you are ready to inject. |
| | Leave the syringes at room temperature for 30 minutes |
| | before injecting. |
| | Do not microwave the syringe, run hot water over them, or |
| | leave them in direct sunlight. |
| | Do not use the syringes if the medicine is frozen. |
| | Do not shake the syringes. |
| | |

Gather supplies

Inspect the syringes and the medicine





Prepare for injection

Choose your injection site



Supplies:
2 alcohol wipes
2 cotton balls or pieces of gauze
1 sharps container (see "Disposing of Omvoh syringe")

Make sure you have the right medicine. The medicine inside should be clear. It may be colourless to slightly yellow.

Do not use the syringe, and dispose of as directed by your healthcare provider if:

- it looks damaged
- the medicine is cloudy, is discoloured, or has particles
- the expiry date printed on the label has passed
- the medicine is frozen

Wash your hands with soap and water before you inject Omvoh.

Your healthcare provider can help you choose the injection site that is best for you.

- You or another person may inject the medicine into your stomach area (abdomen). Do not inject within 5 centimetres of the belly button (navel).
- You or another person may inject the medicine in the front of your thighs. This area should be at least 5 centimetres above the knee and 5 centimetres below the groin.
- Another person may give you the injection in the back of your upper arm.
- **Do not** inject in the exact same spot every time. For example, if your first injection was in your abdomen, your second injection to complete a full dose could be in another spot in your abdomen.
- **Do not** inject into areas where the skin is tender, bruised, red or hard.

Clean the injection site with an alcohol wipe. Let the injection site dry before you inject your medicine.

Injecting Omvoh

- 1 Uncap the syringe
 - Leave the needle cap on until you are ready to inject.
 - Pull the needle cap off and throw it away in your household waste.
 - **Do not** put the needle cap back on. You could damage the needle or stick yourself by accident.
 - **Do not** touch the needle.



2 Insert

- Gently pinch and hold a fold of skin where you will inject.
- Insert the needle at a 45 degree angle

3 Inject

- Slowly push on the thumb pad to push the plunger all the way in until all the medicine is injected.
- The grey syringe plunger should be pushed all the way to the needle end of the syringe.
- You should see the blue plunger rod show through the syringe body when the injection is complete as shown.
- Remove the needle from your skin and gently let go of your skin.
- If you have bleeding at the injection site, press a cotton ball or gauze over the injection site.
- **Do not** rub the injection site.
- **Do not** put the needle cap back on the pre-filled syringe.







Blue plunger rod

Grey syringe plunger

2 injections are required for a full dose. Inject one syringe immediately followed by the other syringe.

Disposing of Omvoh syringe

Throw away the used syringe

• Put the used syringe in a sharps disposal container right away after use. Do not throw the syringe directly into your household waste.



- If you do not have a sharps disposal container, you may use a household container that is:
 - made of a heavy-duty plastic,
 - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
 - upright and stable during use,
 - leak-resistant,
 - properly labelled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away needles and syringes.
- Do not recycle your used sharps disposal container.
- For more information on how to dispose of the container properly, ask your healthcare provider about options available in your area.

Commonly asked questions

Q. What if I let my syringe warm up for longer than 30 minutes before injecting?

A. Your syringe can stay at room temperature up to 30 °C for up to 2 weeks.

Q. What if I see air bubbles in the syringe?

A. It is normal to have air bubbles in the syringe. They will not harm you or affect your dose.

Q. What if there is a drop of liquid on the tip of the needle when I remove the needle cap?

A. It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.

Q. What if I cannot push in the plunger?

A. If the plunger is stuck or damaged:

- Do not continue to use the syringe
- Remove the needle from your skin
- Do not use the syringe. Talk to your doctor or pharmacist to get a new one.

Q. What if there is a drop of liquid or blood on my skin after my injection?

A. This is normal. Press a cotton ball or gauze over the injection site. Do not rub the injection site.

Q. How can I tell if my injection is complete?

A. When your injection is complete:

- The blue plunger rod should show through the body of the syringe.
- The grey syringe plunger should be pushed all the way to the needle end of the syringe.

Read the full package leaflet for Omvoh inside this box to learn more about your medicine.

Last revised in

Package leaflet: Information for the patient

Omvoh 100 mg solution for injection in pre-filled syringe Omvoh 200 mg solution for injection in pre-filled syringe

mirikizumab

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

- 1. What Omvoh is and what it is used for
- 2. What you need to know before you use Omvoh
- 3. How to use Omvoh
- 4. Possible side effects
- 5. How to store Omvoh
- 6. Contents of the pack and other information

1. What Omvoh is and what it is used for

Omvoh contains the active substance mirikizumab, a monoclonal antibody.

Monoclonal antibodies are proteins that recognise and bind specifically to certain target proteins in the body. Omvoh works by attaching to and blocking a protein in the body called IL-23 (interleukin-23), which is involved in inflammation. By blocking the action of IL-23, Omvoh reduces inflammation and other symptoms associated with Crohn's disease.

Crohn's disease

Crohn's disease is a chronic inflammatory disease of the digestive tract. If you have active Crohn's disease, you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Omvoh to reduce signs and symptoms of Crohn's disease such as diarrhoea, abdominal pain, fatigue and urgency.

2. What you need to know before you use Omvoh

Do not use Omvoh

- if you are allergic to mirikizumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Omvoh.
- If you have important active infections (active tuberculosis).

Warnings and precautions

- Talk to your doctor or pharmacist before using this medicine.
- Your doctor will check how well you are before treatment.
- Make sure you tell your doctor about any illness you have before treatment.

Infections

- Omvoh can potentially cause serious infections. Treatment with Omvoh should not be started if you have an active infection until the infection is gone.
- After starting the treatment, tell your doctor right away if you have any symptoms of an infection such as:
 - fever
 chills
 muscle aches
 sore throat
 - cough pain during urination
- Also tell your doctor if you have recently been near anyone who might have tuberculosis.
- Your doctor will examine you and may do a test for tuberculosis before you have Omvoh.
- If your doctor thinks you are at risk of an active tuberculosis, you may be given medicines to treat it.

Vaccinations

Your doctor will check to see if you need any vaccinations before starting treatment. Tell your doctor, pharmacist or nurse if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Allergic reactions

- Omvoh can potentially cause serious allergic reactions.
- Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
 - rash
 fainting
 fainting
 low blood pressure
 swelling of the face, lips, mouth, tongue or throat, trouble breathing
 - dizziness
 sensation of throat tightening or chest tightness.

Liver blood test

Your doctor will conduct blood tests before starting and during treatment with Omvoh to check if your liver is functioning normally. If blood tests are abnormal, your doctor might interrupt therapy with Omvoh and do additional tests on your liver to determine the cause.

Children and adolescents

Omvoh is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Omvoh

Tell your doctor, pharmacist or nurse

- if you are using, have recently used or might use any other medicines.
- if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Omvoh in pregnancy. The effects of Omvoh in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and should use effective contraception while using Omvoh and for at least 10 weeks after the last Omvoh dose.

If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.
Driving and using machines

Omvoh is unlikely to influence your ability to drive and use machines.

Omvoh contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially "sodium -free".

Omvoh contains polysorbate

This medicine contains 0.3 mg/mL of polysorbate 80 in each syringe which is equivalent to 0.9 mg for the maintenance dose to treat Crohn's disease. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How to use Omvoh

Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor, nurse or pharmacist if you are not sure how to use this medicine.

How much Omvoh is given and for how long

Your doctor will decide how much Omvoh you need and for how long. Omvoh is for long-term treatment. Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect.

Crohn's disease

- Treatment start: The first dose of Omvoh is 900 mg (3 vials of 300 mg each) and will be given by your doctor by intravenous infusion (drip in a vein in your arm) over at least 90 minutes. After the first dose, you will receive another dose of Omvoh 900 mg 4 weeks later and again after an additional 4 weeks.
- Maintenance therapy: 4 weeks after the last intravenous infusion, a maintenance dose of Omvoh 300 mg will be given by an injection under the skin ('subcutaneously') and then every 4 weeks. The maintenance dose of 300 mg will be given by using 2 injections: one containing 100 mg (1 mL) of Omvoh and one containing 200 mg (2 mL) of Omvoh. The injections may be administered in any order.

The 200 mg pre-filled syringe is only for treatment of Crohn's disease.

Your doctor or nurse will tell you when to switch to subcutaneous injections. During maintenance therapy you and your doctor or nurse should decide if you should inject Omvoh yourself after training in subcutaneous injection technique. It is important not to try to inject yourself until you have been trained by your doctor or nurse. Your doctor or nurse will offer the necessary training.

A caregiver may also give you your Omvoh injection after proper training. Use a reminder method such as notes in a calendar or diary to help you remember when to take your next dose so that you avoid missing or repeating doses.

If you receive more Omvoh than you should

If you have received more Omvoh than you should or the dose has been given sooner than prescribed, inform your doctor.

If you forget to use Omvoh

If you have forgotten to inject a dose of Omvoh, inject as soon as possible. Thereafter, resume dosing every 4 weeks.

If you stop using Omvoh

You should not stop using Omvoh without speaking to your doctor first. If you stop treatment, symptoms of your disease may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common (may affect more than 1 in 10 people)

- Injection site reactions (e.g. red skin, pain)

Common (may affect up to 1 in 10 people):

- Upper respiratory tract infections (nose and throat infections)
- Joint pain
- Headache
- Rash

Uncommon (may affect up to 1 in 100 people):

- Shingles
- Infusion-related allergic reaction (e.g. itch, hives)
- Increase in the level of liver enzymes in your blood.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in <u>Appendix V</u>. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Omvoh

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and on the outer carton after "EXP". The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C). Do not freeze.

Do not microwave the syringes, run hot water over them, or leave them in direct sunlight. **Do not** shake your pre-filled syringe.

Store in the original packaging in order to protect from light. Omvoh may be stored unrefrigerated for up to 2 weeks at a temperature not above 30 °C. If these conditions are exceeded, Omvoh must be discarded.

Do not use this medicine if you notice that the pre-filled syringe is damaged, or the medicine is cloudy, distinctly brown, or has particles in it.

This medicine is for single use only.

Do not throw away any medicines via wastewater. Ask your doctor, nurse or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Omvoh contains

- The active substance is mirikizumab. One pre-filled syringe contains 100 mg of mirikizumab in 1 mL solution and one pre-filled syringe contains 200 mg of mirikizumab in 2 mL solution.
- The other ingredients are histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections.

What Omvoh looks like and contents of the pack

Omvoh is a solution in a clear glass cartridge encased in a disposable, single-use syringe. Its colour may vary from colourless to slightly yellow.

Omvoh is available in packs containing 2 pre-filled syringes and in multipacks comprising 3 cartons, each containing 2 pre-filled syringes. Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands

Manufacturer

Lilly France S.A.S. Rue du Colonel Lilly 67640 Fegersheim France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgique/België/Belgien

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

България ТП "Ели Лили Недерланд" Б.В. - България тел. + 359 2 491 41 40

Česká republika ELI LILLY ČR, s.r.o. Tel: + 420 234 664 111

Danmark Eli Lilly Danmark A/S Tlf.: +45 45 26 60 00

Deutschland Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222

Eesti Eli Lilly Nederland B.V. Tel: +372 6 817 280 **Lietuva** Eli Lilly Lietuva Tel. +370 (5) 2649600

Luxembourg/Luxemburg

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

Magyarország

Lilly Hungária Kft. Tel: + 36 1 328 5100

Malta

Charles de Giorgio Ltd. Tel: + 356 25600 500

Nederland

Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800

Norge Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00

Ελλάδα ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: +30 210 629 4600

España Lilly S.A. Tel: + 34-91 663 50 00

France Lilly France Tél: +33-(0) 1 55 49 34 34

Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999

Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377

Ísland Icepharma hf. Sími + 354 540 8000

Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42571

Κύπρος Phadisco Ltd Τηλ: +357 22 715000

Latvija Eli Lilly (Suisse) S.A. Pārstāvniecība Latvijā Tel: +371 67364000

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: <u>https://www.ema.europa.eu</u>.

Österreich Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780

Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00

Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600

România Eli Lilly România S.R.L. Tel: + 40 21 4023000

Slovenija Eli Lilly farmacevtska družba, d.o.o. Tel: +386 (0)1 580 00 10

Slovenská republika Eli Lilly Slovakia, s.r.o. Tel: + 421 220 663 111

Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358-(0) 9 85 45 250

Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800

Instructions for use

Omvoh 100 mg solution for injection in pre-filled syringe Omvoh 200 mg solution for injection in pre-filled syringe

mirikizumab

2 pre-filled syringes: 1 syringe of 100 mg and 1 syringe of 200 mg



Read this before you inject Omvoh. Follow all the step-by-step instructions.

- 2 Omvoh injections are required for a full dose to treat Crohn's disease: one syringe with 100 mg and one syringe with 200 mg.
- Inject one Omvoh pre-filled syringe followed right away by the other Omvoh pre-filled syringe.

Also keep in mind:

- Your healthcare provider should show you how to prepare and inject Omvoh using the pre-filled syringe. **Do not** inject yourself or someone else until you have been shown how to inject Omvoh.
- Each Omvoh pre-filled syringe is for one-time use only. Do not share or reuse your syringe. You may give or get an infection.
- Your healthcare provider may help you decide where on your body to inject your dose. You can also read the "Choose your injection site" section of these instructions to help you choose which area can work best for you.
- If you have vision problems, do not use Omvoh pre-filled syringe without help from a caregiver.
- Keep the Instructions for use and refer to them as needed.

Before you use the Omvoh syringes, read and carefully follow all the step-by-step instructions.

2 syringes = full 300 mg dose

After your first injection, **choose** a new injection site at least 5 centimeters away and clean it. With your second syringe, **repeat steps 1-3** immediately after your first injection. **You must inject 2 syringes to complete your full 300 mg dose.**

Parts of the Omvoh pre-filled syringe

Inject both syringes in any order for a full 300 mg dose. The 200 mg syringe is larger than the 100 mg syringe.



100 mg + 200 mg = 1 Full dose

IMPORTANT:

- 2 injections are required for a full dose to treat Crohn's disease: one syringe with 100 mg and one syringe with 200 mg.
- Inject one syringe followed right away by the other syringe.

Preparing to inject Omvoh

| Take the syringes from the refrigerator | Take 2 syringes from the refrigerator. Leave the needle caps on until you are ready to inject. Leave the syringes at room temperature for 45 minutes before injecting. Do not microwave the syringe, run hot water over them, or leave them in direct sunlight. Do not use the syringes if the medicine is frozen. Do not shake the syringes. |
|--|--|
| Gather supplies | Supplies: 2 alcohol wipes 2 cotton balls or pieces of gauze 1 sharps container (see "Disposing of Omvoh syringe") |
| Inspect the syringes and the medicine Expiry date | Make sure you have the right medicine. The medicine inside should be clear. It may be colourless to slightly yellow. |
| | Do not use the syringe, and dispose of as directed by your healthcare provider if: it looks damaged the medicine is cloudy, is discoloured, or has particles the expiry date printed on the label has passed the medicine is frozen |
| Prepare for injection | Wash your hands with soap and water before you inject Omvoh. |
| Choose your injection site | Your healthcare provider can help you choose the injection site that is best for you. |
| | • You or another person may inject the medicine into your stomach area (abdomen). Do not inject within 5 centimetres of the belly button (navel). |

You or another

person may inject into these areas.

Another person

this area.

should inject into

- You or another person may inject the medicine in the front of your thighs. This area should be at least 5 centimetres above the knee and 5 centimetres below the groin.
- Another person may give you the injection in the back of your upper arm.
- **Do not** inject in the exact same spot every time. For example, if your first injection was in your abdomen, your second injection to complete a full dose could be in another spot in your abdomen.
- **Do not** inject into areas where the skin is tender, bruised, red or hard.

Clean the injection site with an alcohol wipe. Let the injection site dry before you inject your medicine.

Injecting Omvoh

- 1 Uncap the syringe
 - Leave the needle cap on until you are ready to inject.
 - Pull the needle cap off and throw it away in your household waste.
 - **Do not** put the needle cap back on. You could damage the needle or stick yourself by accident.
 - **Do not** touch the needle.



2 Insert

- Gently pinch and hold a fold of skin where you will inject.
- Insert the needle at a 45 degree angle

3 Inject

- Slowly push on the thumb pad to push the plunger all the way in until all the medicine is injected.
- The grey syringe plunger should be pushed all the way to the needle end of the syringe.
- You should see the blue plunger rod show through the syringe body when the injection is complete as shown.
- Remove the needle from your skin and gently let go of your skin.
- If you have bleeding at the injection site, press a cotton ball or gauze over the injection site.
- **Do not** rub the injection site.
- **Do not** put the needle cap back on the pre-filled syringe.







2 injections are required for a full dose. Inject one syringe immediately followed by the other syringe.

Disposing of Omvoh syringe

Throw away the used syringe

• Put the used syringe in a sharps disposal container right away after use. Do not throw the syringe directly into your household waste.



- If you do not have a sharps disposal container, you may use a household container that is:
 - made of a heavy-duty plastic,
 - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
 - upright and stable during use,
 - leak-resistant,
 - properly labelled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away needles and syringes.
- Do not recycle your used sharps disposal container.
- For more information on how to dispose of the container properly, ask your healthcare provider about options available in your area.

Commonly asked questions

Q. What if I let my syringe warm up for longer than 45 minutes before injecting?

A. Your syringe can stay at room temperature up to 30 °C for up to 2 weeks.

Q. What if I see air bubbles in the syringe?

A. It is normal to have air bubbles in the syringe. They will not harm you or affect your dose.

Q. What if there is a drop of liquid on the tip of the needle when I remove the needle cap?

A. It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.

Q. What if I cannot push in the plunger?

A. If the plunger is stuck or damaged:

- **Do not** continue to use the syringe
- Remove the needle from your skin
- Do not use the syringe. Talk to your doctor or pharmacist to get a new one.

Q. What if there is a drop of liquid or blood on my skin after my injection?

A. This is normal. Press a cotton ball or gauze over the injection site. Do not rub the injection site.

Q. How can I tell if my injection is complete?

A. When your injection is complete:

- The blue plunger rod should show through the body of the syringe.
- The grey syringe plunger should be pushed all the way to the needle end of the syringe.

Read the full package leaflet for Omvoh inside this box to learn more about your medicine.

Last revised in

Package leaflet: Information for the patient

Omvoh 100 mg solution for injection in pre-filled pen

mirikizumab

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

- 1. What Omvoh is and what it is used for
- 2. What you need to know before you use Omvoh
- 3. How to use Omvoh
- 4. Possible side effects
- 5. How to store Omvoh
- 6. Contents of the pack and other information

1. What Omvoh is and what it is used for

Omvoh contains the active substance mirikizumab, a monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind specifically to certain target proteins in the body. Omvoh works by attaching to and blocking a protein in the body called IL-23 (interleukin-23), which is involved in inflammation. By blocking the action of IL-23, Omvoh reduces inflammation and other symptoms associated with ulcerative colitis.

Ulcerative colitis

Ulcerative colitis is a chronic inflammatory disease of the large bowel. If you have ulcerative colitis, you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Omvoh to reduce signs and symptoms of ulcerative colitis such as diarrhoea, abdominal pain, urgency and rectal bleeding.

2. What you need to know before you use Omvoh

Do not use Omvoh

- if you are allergic to mirikizumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Omvoh.
- If you have important active infections (active tuberculosis).

Warnings and precautions

- Talk to your doctor or pharmacist before using this medicine.
- Your doctor will check how well you are before treatment.
- Make sure you tell your doctor about any illness you have before treatment.

Infections

- Omvoh can potentially cause serious infections. Treatment with Omvoh should not be started if you have an active infection until the infection is gone.
- After starting the treatment, tell your doctor right away if you have any symptoms of an infection such as:
 - \circ fever \circ shortness of breath
 - chills runny nose
 - muscle aches

o cough

- \circ runny nose
- \circ sore throat
- pain during urination
- Also tell your doctor if you have recently been near anyone who might have tuberculosis.
- Your doctor will examine you and may do a test for tuberculosis before you have Omvoh.
- If your doctor thinks you are at risk of an active tuberculosis, you may be given medicines to treat it.

Vaccinations

Your doctor will check to see if you need any vaccinations before starting treatment. Tell your doctor, pharmacist or nurse if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Allergic reactions

- Omvoh can potentially cause serious allergic reactions.
- Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
 - o rash
 - o fainting
- o low blood pressure
- swelling of the face, lips, mouth, tongue or throat, trouble breathing
- o dizziness
- sensation of throat tightening or chest tightness.

Liver blood test

Your doctor will conduct blood tests before starting and during treatment with Omvoh to check if your liver is functioning normally. If blood tests are abnormal, your doctor might interrupt therapy with Omvoh and do additional tests on your liver to determine the cause.

Children and adolescents

Omvoh is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Omvoh

Tell your doctor, pharmacist or nurse

- if you are using, have recently used or might use any other medicines.
- if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Omvoh in pregnancy. The effects of Omvoh in pregnant women are not known. If you are a woman of childbearing potential,

you are advised to avoid becoming pregnant and should use effective contraception while using Omvoh and for at least 10 weeks after the last Omvoh dose.

If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.

Driving and using machines

Omvoh is unlikely to influence your ability to drive and use machines.

Omvoh contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially "sodium -free".

Omvoh contains polysorbate

This medicine contains 0.3 mg/mL of polysorbate 80 in each pen which is equivalent to 0.6 mg for the maintenance dose to treat ulcerative colitis. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How to use Omvoh

Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor, nurse or pharmacist if you are not sure how to use this medicine.

How much Omvoh is given and for how long

Your doctor will decide how much Omvoh you need and for how long. Omvoh is for long-term treatment. Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect.

Ulcerative colitis

• Treatment start: The first dose of Omvoh is 300 mg and will be given by your doctor by intravenous infusion (drip in a vein in your arm) over at least 30 minutes. After the first dose, you will receive another dose of Omvoh 300 mg 4 weeks later and again after an additional 4 weeks.

If you do not have adequate therapeutic response after these 3 infusions, your doctor might consider continuing intravenous infusions at weeks 12, 16 and 20.

Maintenance therapy: 4 weeks after the last intravenous infusion, a maintenance dose of Omvoh 200 mg will be given by an injection under the skin ('subcutaneously') and then every 4 weeks. The maintenance dose of 200 mg will be given by using 2 injections each containing 100 mg of Omvoh. If you lose response after receiving the maintenance dose of Omvoh, your doctor may decide to give you 3 doses of Omvoh by intravenous infusions.

Your doctor or nurse will tell you when to switch to subcutaneous injections. During maintenance therapy you and your doctor or nurse should decide if you should inject Omvoh yourself after training in subcutaneous injection technique. It is important not to try to inject yourself until you have been trained by your doctor or nurse. Your doctor or nurse will offer the necessary training. A caregiver may also give you your Omvoh injection after proper training. Use a reminder method such as notes in a calendar or diary to help you remember when to

If you receive more Omvoh than you should

If you have received more Omvoh than you should or the dose has been given sooner than prescribed, inform your doctor.

If you forget to use Omvoh

If you have forgotten to inject a dose of Omvoh, inject as soon as possible. Thereafter, resume dosing every 4 weeks.

If you stop using Omvoh

You should not stop using Omvoh without speaking to your doctor first. If you stop treatment, symptoms of ulcerative colitis may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common (may affect more than 1 in 10 people)

- Injection site reactions (e.g. red skin, pain)

Common (may affect up to 1 in 10 people):

- Upper respiratory tract infections (nose and throat infections)
- Joint pain
- Headache
- Rash

Uncommon (may affect up to 1 in 100 people):

- Shingles
- Infusion-related allergic reaction (e.g. itch, hives)
- Increase in the level of liver enzymes in your blood.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in <u>Appendix V</u>. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Omvoh

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and on the outer carton after "EXP". The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C). Do not freeze.

Do not microwave the pens, run hot water over them, or leave them in direct sunlight. **Do not** shake your pre-filled pen.

Store in the original packaging in order to protect from light. Omvoh may be stored unrefrigerated for up to 2 weeks at a temperature not above 30 °C. If these conditions are exceeded, Omvoh must be discarded. Do not use this medicine if you notice that the pre-filled pen is damaged, or the medicine is cloudy, distinctly brown, or has particles in it.

This medicine is for single use only.

Do not throw away any medicines via wastewater. Ask your doctor, nurse or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Omvoh contains

- The active substance is mirikizumab.
- Each pre-filled pen contains 100 mg of mirikizumab in 1 mL solution.
- The other ingredients are histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections.

What Omvoh looks like and contents of the pack

Omvoh is a solution in a clear glass cartridge encased in a disposable, single-use pen. Its colour may vary from colourless to slightly yellow.

Omvoh is available in packs containing 2 pre-filled pens, in multipacks comprising 2 cartons, each containing 2 pre-filled pens and in multipacks comprising 3 cartons, each containing 2 pre-filled pens.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands

Manufacturer

Lilly France S.A.S. Rue du Colonel Lilly 67640 Fegersheim France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgique/België/Belgien Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

България ТП "Ели Лили Недерланд" Б.В. - България тел. + 359 2 491 41 40

Česká republika ELI LILLY ČR, s.r.o. Tel: + 420 234 664 111

Danmark Eli Lilly Danmark A/S Tlf.: +45 45 26 60 00

Lietuva Eli Lilly Lietuva Tel. +370 (5) 2649600

Luxembourg/Luxemburg

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

Magyarország Lilly Hungária Kft. Tel: + 36 1 328 5100

Malta Charles de Giorgio Ltd. Tel: + 356 25600 500 **Deutschland** Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222

Eesti Eli Lilly Nederland B.V. Tel: +372 6 817 280

Ελλάδα ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: +30 210 629 4600

España Lilly S.A. Tel: + 34-91 663 50 00

France Lilly France Tél: +33-(0) 1 55 49 34 34

Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999

Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377

Ísland Icepharma hf. Sími + 354 540 8000

Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42571

Κύπρος Phadisco Ltd Τηλ: +357 22 715000

Latvija Eli Lilly (Suisse) S.A. Pārstāvniecība Latvijā Tel: +371 67364000

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: <u>https://www.ema.europa.eu</u>.

Nederland Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800

Norge Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00

Österreich Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780

Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00

Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600

România Eli Lilly România S.R.L. Tel: + 40 21 4023000

Slovenija Eli Lilly farmacevtska družba, d.o.o. Tel: +386 (0)1 580 00 10

Slovenská republika Eli Lilly Slovakia, s.r.o. Tel: + 421 220 663 111

Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358-(0) 9 85 45 250

Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800

Instructions for use

Omvoh 100 mg solution for injection in pre-filled pen

mirikizumab

2 pre-filled pens: 1 pen 100 mg and 1 pen 100 mg



Read this before you inject Omvoh. Follow all the step-by-step instructions.

- 2 Omvoh injections are required for a full dose to treat ulcerative colitis.
- Inject 1 Omvoh pen followed right away by the other Omvoh pen.

Also keep in mind:

- Your healthcare provider should show you how to prepare and inject Omvoh using the pen. **Do not** inject yourself or someone else until you have been shown how to inject Omvoh.
- Each Omvoh pen is for one-time use only. Do not share or reuse your pen. You may give or get an infection.
- Your healthcare provider may help you decide where on your body to inject your dose. You can also read the "Choose your injection site" section of these instructions to help you choose which area can work best for you.
- If you have vision or hearing problems, do not use Omvoh pen without help from a caregiver.
- Keep the Instructions for use and refer to them as needed.

Before you use the Omvoh pens, read and carefully follow all the step-by-step instructions.

Parts of the Omvoh pen



Bottom

100 mg + 100 mg = 1 Full dose

IMPORTANT:

- 2 injections are required for a full dose to treat ulcerative colitis.
- Inject 1 pen followed right away by the other pen.

Take the pens from the refrigerator

Gather supplies

Inspect the pens and the medicine



Prepare for injection

Choose your injection site



Take 2 Omvoh pens from the refrigerator.
Leave the grey base caps on until you are ready to inject.
Leave the pens at room temperature for 30 minutes before injecting.
Do not microwave the pens, run hot water over them, or leave them in direct sunlight.
Do not use the pens if the medicine is frozen.
Do not shake.

Supplies:

- 2 alcohol wipes
- 2 cotton balls or pieces of gauze
- 1 sharps container (see "Disposing of Omvoh pens")

Make sure you have the right medicine. The medicine inside should be clear. It may be colourless to slightly yellow.

Do not use the pens, and dispose of as directed by your healthcare provider if:

- it looks damaged
- the medicine is cloudy, is discoloured, or has particles
- the expiry date printed on the label has passed
- the medicine is frozen

Wash your hands with soap and water before you inject Omvoh.

Your healthcare provider can help you choose the injection site that is best for you.

- You or another person may inject the medicine into your stomach area (abdomen). Do not inject within 5 centimetres of the belly button (navel).
- You or another person may inject the medicine in the front of your thighs. This area should be at least 5 centimetres above the knee and 5 centimetres below the groin.
- Another person may give you the injection in the back of your upper arm.
- **Do not** inject in the exact same spot every time. For example, if your first injection was in your abdomen, your second injection to complete a full dose could be in another spot in your abdomen.
- **Do not** inject into areas where the skin is tender, bruised, red or hard.

Clean the injection site with an alcohol wipe. Let the injection site dry before you inject your medicine.

Injecting Omvoh

- 1 Uncap the pen Make sure the pen is locked. Leave the grey base cap on until you are ready to inject. • Twist off the grey base cap and throw Needle it away in your household waste. • Do not put the grey base cap back on – this could damage the needle.
 - **Do not** touch the needle.



Clear base

10

seconds

Place and Unlock

• Place and hold the clear base flat and firmly against your skin.

Keep the base on your skin and turn the lock ring to the unlock position.

3 Press and Hold for up to 10 Seconds

- Press and hold the blue injection button. You will hear a loud click (injection started).
- Keep holding the clear base firmly against your skin. You will hear a second loud click in about 10 seconds after the first one (injection completed).
- You will know the injection is complete when the grey plunger is visible.
- Remove the pen from your skin.
- If you have bleeding at the injection site, press a cotton ball or gauze over the injection site.
- Do not rub the injection site.



2 injections are required for a full dose. Inject one pen immediately followed by the other pen.

2

Disposing of Omvoh pens

Throw away the used pens

• Put the used pen in a sharps disposal container right away after use. Do not throw the pen directly into your household waste.



- If you do not have a sharps disposal container, you may use a household container that is:
 - made of a heavy-duty plastic,
 - can be closed with a tight fitting, puncture-resistant lid, without sharps being able to come out,
 - upright and stable during use,
 - leak-resistant,
 - properly labelled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away needles and pens.
- Do not recycle your used sharps disposal container.
- For more information on how to dispose of the container properly, ask your healthcare provider about options available in your area.

Commonly asked questions

Q. What if I let my pens warm up for longer than 30 minutes before injecting?

A. Your pen can stay at room temperature up to 30 °C for up to 2 weeks.

Q. What if I see air bubbles in the pen?

A. It is normal to have air bubbles in the pen. They will not harm you or affect your dose.

Q. What if there is a drop of liquid on the tip of the needle when I remove the grey base cap?

A. It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.

Q. What if I unlocked the pen and pressed the blue injection button down until the injection is complete?

A. Do not remove the grey base cap. Do not use the pen. Talk to your doctor or pharmacist to get a new one.

Q. Do I need to hold the blue injection button down until the injection is complete?

A. You do not need to hold the blue injection button down, but it may help you keep the pen steady and firm against your skin.

Q. What if the needle did not retract after my injection?

A. Do not touch the needle or replace the grey base cap. Store the pen in a safe place to avoid an accidental needlestick and contact your doctor, pharmacist or nurse.

Q. What if there is a drop of liquid or blood on my skin after my injection?

A. This is normal. Press a cotton ball or gauze over the injection site. Do not rub the injection site.

Q. What if I heard more than 2 clicks during my injection – 2 loud clicks and a soft one. Did I get my complete injection?

A. Some patients may hear a soft click right before the second loud click. That is the normal operation of the pen. **Do not** remove the pen from your skin until you hear the second loud click.

Q. How can I tell if my injection is complete?

A. After you press the blue injection button, you will hear 2 loud clicks. The second loud click tells you that your injection is complete. You will also see the grey plunger at the top of the clear base.

Read the full package leaflet for Omvoh inside this box to learn more about your medicine.

Last revised in

Package leaflet: Information for the patient

Omvoh 100 mg solution for injection in pre-filled pen Omvoh 200 mg solution for injection in pre-filled pen

mirikizumab

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

- 1. What Omvoh is and what it is used for
- 2. What you need to know before you use Omvoh
- 3. How to use Omvoh
- 4. Possible side effects
- 5. How to store Omvoh
- 6. Contents of the pack and other information

1. What Omvoh is and what it is used for

Omvoh contains the active substance mirikizumab, a monoclonal antibody.

Monoclonal antibodies are proteins that recognise and bind specifically to certain target proteins in the body. Omvoh works by attaching to and blocking a protein in the body called IL-23 (interleukin-23), which is involved in inflammation. By blocking the action of IL-23, Omvoh reduces inflammation and other symptoms associated with Crohn's disease.

Crohn's disease

Crohn's disease is a chronic inflammatory disease of the digestive tract. If you have active Crohn's disease, you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Omvoh to reduce signs and symptoms of Crohn's disease such as diarrhoea, abdominal pain, fatigue and urgency.

2. What you need to know before you use Omvoh

Do not use Omvoh

- if you are allergic to mirikizumab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Omvoh.
- If you have important active infections (active tuberculosis).

Warnings and precautions

- Talk to your doctor or pharmacist before using this medicine.
- Your doctor will check how well you are before treatment.
- Make sure you tell your doctor about any illness you have before treatment.

Infections

- Omvoh can potentially cause serious infections. Treatment with Omvoh should not be started if you have an active infection until the infection is gone.
- After starting the treatment, tell your doctor right away if you have any symptoms of an infection such as:
 - fever
 chills
 muscle aches
 sore throat
 - cough pain during urination
- Also tell your doctor if you have recently been near anyone who might have tuberculosis.
- Your doctor will examine you and may do a test for tuberculosis before you have Omvoh.
- If your doctor thinks you are at risk of an active tuberculosis, you may be given medicines to treat it.

Vaccinations

Your doctor will check to see if you need any vaccinations before starting treatment. Tell your doctor, pharmacist or nurse if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Allergic reactions

- Omvoh can potentially cause serious allergic reactions.
- Stop using Omvoh and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
 - rash
 fainting
 fainting
 welling of the face, lips, mouth, tongue or throat, trouble breathing
 - dizziness
 sensation of throat tightening or chest tightness.

Liver blood test

Your doctor will conduct blood tests before starting and during treatment with Omvoh to check if your liver is functioning normally. If blood tests are abnormal, your doctor might interrupt therapy with Omvoh and do additional tests on your liver to determine the cause.

Children and adolescents

Omvoh is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Omvoh

Tell your doctor, pharmacist or nurse

- if you are using, have recently used or might use any other medicines.
- if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Omvoh in pregnancy. The effects of Omvoh in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and should use effective contraception while using Omvoh and for at least 10 weeks after the last Omvoh dose.

If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.

Driving and using machines

Omvoh is unlikely to influence your ability to drive and use machines.

Omvoh contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially "sodium -free".

Omvoh contains polysorbate

This medicine contains 0.3 mg/mL of polysorbate 80 in each pen which is equivalent to 0.9 mg for the maintenance dose to treat Crohn's disease. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How to use Omvoh

Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor, nurse or pharmacist if you are not sure how to use this medicine.

How much Omvoh is given and for how long

Your doctor will decide how much Omvoh you need and for how long. Omvoh is for long-term treatment. Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect.

Crohn's disease

- Treatment start: The first dose of Omvoh is 900 mg (3 vials of 300 mg each) and will be given by your doctor by intravenous infusion (drip in a vein in your arm) over at least 90 minutes. After the first dose, you will receive another dose of Omvoh 900 mg 4 weeks later and again after an additional 4 weeks.
- Maintenance therapy: 4 weeks after the last intravenous infusion, a maintenance dose of Omvoh 300 mg will be given by an injection under the skin ('subcutaneously') and then every 4 weeks. The maintenance dose of 300 mg will be given by using 2 injections: one containing 100 mg (1 mL) of Omvoh and one containing 200 mg (2 mL) Omvoh. The injections may be administered in any order.

The 200 mg pre-filled pen is only for treatment of Crohn's disease.

Your doctor or nurse will tell you when to switch to subcutaneous injections. During maintenance therapy you and your doctor or nurse should decide if you should inject Omvoh yourself after training in subcutaneous injection technique. It is important not to try to inject yourself until you have been trained by your doctor or nurse. Your doctor or nurse will offer the necessary training.

A caregiver may also give you your Omvoh injection after proper training.

Use a reminder method such as notes in a calendar or diary to help you remember when to take your next dose so that you avoid missing or repeating doses.

If you receive more Omvoh than you should

If you have received more Omvoh than you should or the dose has been given sooner than prescribed, inform your doctor.

If you forget to use Omvoh

If you have forgotten to inject a dose of Omvoh, inject as soon as possible. Thereafter, resume dosing every 4 weeks.

If you stop using Omvoh

You should not stop using Omvoh without speaking to your doctor first. If you stop treatment, symptoms of your disease may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common (may affect more than 1 in 10 people)

- Injection site reactions (e.g. red skin, pain)

Common (may affect up to 1 in 10 people):

- Upper respiratory tract infections (nose and throat infections)
- Joint pain
- Headache
- Rash

Uncommon (may affect up to 1 in 100 people):

- Shingles
- Infusion-related allergic reaction (e.g. itch, hives)
- Increase in the level of liver enzymes in your blood.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in <u>Appendix V</u>. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Omvoh

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and on the outer carton after "EXP". The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C). Do not freeze.

Do not microwave the pens, run hot water over them, or leave them in direct sunlight. **Do not** shake your pre-filled pen.

Store in the original packaging in order to protect from light. Omvoh may be stored unrefrigerated for up to 2 weeks at a temperature not above 30 °C. If these conditions are exceeded, Omvoh must be discarded.

Do not use this medicine if you notice that the pre-filled pen is damaged, or the medicine is cloudy, distinctly brown, or has particles in it.

This medicine is for single use only.

Do not throw away any medicines via wastewater. Ask your doctor, nurse or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Omvoh contains

- The active substance is mirikizumab.
 One pre-filled pen contains 100 mg of mirikizumab in 1 mL solution and one pre-filled pen contains 200 mg of mirikizumab in 2 mL solution.
- The other ingredients are histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections.

What Omvoh looks like and contents of the pack

Omvoh is a solution in a clear glass cartridge encased in a disposable, single-use pen. Its colour may vary from colourless to slightly yellow.

Omvoh is available in pack containing 2 pre-filled pens and in multipacks comprising 3 cartons, each containing 2 pre-filled pens. Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands

Manufacturer

Lilly France S.A.S. Rue du Colonel Lilly 67640 Fegersheim France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgique/België/Belgien

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

България ТП "Ели Лили Недерланд" Б.В. - България тел. + 359 2 491 41 40

Česká republika ELI LILLY ČR, s.r.o. Tel: + 420 234 664 111

Danmark Eli Lilly Danmark A/S Tlf.: +45 45 26 60 00

Deutschland Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2222

Eesti Eli Lilly Nederland B.V. Lietuva Eli Lilly Lietuva Tel. +370 (5) 2649600

Luxembourg/Luxemburg

Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32-(0)2 548 84 84

Magyarország

Lilly Hungária Kft. Tel: + 36 1 328 5100

Malta

Charles de Giorgio Ltd. Tel: + 356 25600 500

Nederland Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800

Norge Eli Lilly Norge A.S. Tel: +372 6 817 280

Ελλάδα ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Τηλ: +30 210 629 4600

España Lilly S.A. Tel: + 34-91 663 50 00

France Lilly France Tél: +33-(0) 1 55 49 34 34

Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999

Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377

Ísland Icepharma hf. Sími + 354 540 8000

Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42571

Κύπρος Phadisco Ltd Τηλ: +357 22 715000

Latvija Eli Lilly (Suisse) S.A. Pārstāvniecība Latvijā Tel: +371 67364000

This leaflet was last revised in

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: <u>https://www.ema.europa.eu</u>.

Tlf: + 47 22 88 18 00

Österreich Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780

Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00

Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600

România Eli Lilly România S.R.L. Tel: + 40 21 4023000

Slovenija Eli Lilly farmacevtska družba, d.o.o. Tel: +386 (0)1 580 00 10

Slovenská republika Eli Lilly Slovakia, s.r.o. Tel: + 421 220 663 111

Suomi/Finland Oy Eli Lilly Finland Ab Puh/Tel: + 358-(0) 9 85 45 250

Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800

Instructions for use

Omvoh 100 mg solution for injection in pre-filled pen Omvoh 200 mg solution for injection in pre-filled pen

mirikizumab

2 pre-filled pens: 1 pen 100 mg and 1 pen 200 mg



Read this before you inject Omvoh. Follow all the step-by-step instructions.

- 2 Omvoh injections are required for a full dose to treat Crohn's disease: one pen with 100 mg and one pen with 200 mg.
- Inject one Omvoh pen followed right away by the other Omvoh pen.

Also keep in mind:

- Your healthcare provider should show you how to prepare and inject Omvoh using the pen. **Do not** inject yourself or someone else until you have been shown how to inject Omvoh.
- Each Omvoh pen is for one-time use only. Do not share or reuse your pen. You may give or get an infection.
- Your healthcare provider may help you decide where on your body to inject your dose. You can also read the "Choose your injection site" section of these instructions to help you choose which area can work best for you.
- If you have vision or hearing problems, do not use Omvoh pen without help from a caregiver.
- Keep the Instructions for use and refer to them as needed.

Before you use the Omvoh pens, read and carefully follow all the step-by-step instructions.

2 Pens = full 300 mg dose

After your first injection, **choose** a new injection site at least 5 centimeters away and clean it. With your second Pen, **repeat steps 1-3** immediately after your first injection. **You must inject 2 Pens to complete your full 300 mg dose.**

Parts of the Omvoh pen

Inject both Pens in any order for a full 300 mg dose. The 200 mg Pen is larger than the 100 mg Pen.



Bottom

100 mg + 200 mg = 1 Full dose

IMPORTANT:

• 2 injections are required for a full dose to treat Crohn's disease: one pen with 100 mg and one pen with 200 mg.

• Inject one pen followed right away by the other pen.

Take the pens from the refrigerator

Gather supplies

Inspect the pens and the medicine

Expiry date



Prepare for injection

Choose your injection site



You or another person may inject into these areas.



Another person should inject into this area. Take 2 Omvoh pens from the refrigerator.
Leave the grey base caps on until you are ready to inject.
Leave the pens at room temperature for 45 minutes before injecting.
Do not microwave the pens, run hot water over them, or leave them in direct sunlight.
Do not use the pens if the medicine is frozen.
Do not shake.

Supplies:

- 2 alcohol wipes
- 2 cotton balls or pieces of gauze
- 1 sharps container (see "Disposing of Omvoh pens")

Make sure you have the right medicine. The medicine inside should be clear. It may be colourless to slightly yellow.

Do not use the pens, and dispose of as directed by your healthcare provider if:

- it looks damaged
- the medicine is cloudy, is discoloured, or has particles
- the expiry date printed on the label has passed
- the medicine is frozen

Wash your hands with soap and water before you inject Omvoh.

Your healthcare provider can help you choose the injection site that is best for you.

- You or another person may inject the medicine into your stomach area (abdomen). Do not inject within 5 centimetres of the belly button (navel).
- You or another person may inject the medicine in the front of your thighs. This area should be at least 5 centimetres above the knee and 5 centimetres below the groin.
- Another person may give you the injection in the back of your upper arm.
- **Do not** inject in the exact same spot every time. For example, if your first injection was in your abdomen, your second injection to complete a full dose could be in another spot in your abdomen.
- **Do not** inject into areas where the skin is tender, bruised, red or hard.

Clean the injection site with an alcohol wipe. Let the injection site dry before you inject your medicine.

1 Uncap the pen

Make sure the pen is locked.

Leave the grey base cap on until you are ready to inject.

- Twist off the grey base cap and throw it away in your household waste.
- **Do not** put the grey base cap back on this could damage the needle.
- **Do not** touch the needle.



Clear base

15

seconds

Place and Unlock

2

• Place and hold the clear base flat and firmly against your skin.

Keep the base on your skin and turn the lock ring to the **unlock** position.



- Press and hold the blue injection button. You will hear a loud click (injection started).
- Keep holding the clear base firmly against your skin. You will hear a second loud click in about 15 seconds after the first one (injection completed).
- You will know the injection is complete when the grey plunger is visible.
- Remove the pen from your skin.
- If you have bleeding at the injection site, press a cotton ball or gauze over the injection site.
- **Do not** rub the injection site.



2 injections are required for a full dose. Inject one pen immediately followed by the other pen.

Disposing of Omvoh pens

Throw away the used pens

• Put the used pen in a sharps disposal container right away after use. Do not throw the pen directly into your household waste.



- If you do not have a sharps disposal container, you may use a household container that is:
 - made of a heavy-duty plastic,
 - can be closed with a tight fitting, puncture-resistant lid, without sharps being able to come out,
 - upright and stable during use,
 - leak-resistant,
 - properly labelled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away needles and pens.
- Do not recycle your used sharps disposal container.
- For more information on how to dispose of the container properly, ask your healthcare provider about options available in your area.

Commonly asked questions

Q. What if I let my pens warm up for longer than 45 minutes before injecting?

A. Your pen can stay at room temperature up to 30 °C for up to 2 weeks.

Q. What if I see air bubbles in the pen?

A. It is normal to have air bubbles in the pen. They will not harm you or affect your dose.

Q. What if there is a drop of liquid on the tip of the needle when I remove the grey base cap?

A. It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.

Q. What if I unlocked the pen and pressed the blue injection button down until the injection is complete?

A. Do not remove the grey base cap. Do not use the pen. Talk to your doctor or pharmacist to get a new one.

Q. Do I need to hold the blue injection button down until the injection is complete?

A. You do not need to hold the blue injection button down, but it may help you keep the pen steady and firm against your skin.

Q. What if the needle did not retract after my injection?

A. Do not touch the needle or replace the grey base cap. Store the pen in a safe place to avoid an accidental needlestick and contact your doctor, pharmacist or nurse.

Q. What if there is a drop of liquid or blood on my skin after my injection?

A. This is normal. Press a cotton ball or gauze over the injection site. Do not rub the injection site.

Q. What if I heard more than 2 clicks during my injection – 2 loud clicks and a soft one. Did I get my complete injection?

A. Some patients may hear a soft click right before the second loud click. That is the normal operation of the pen. **Do not** remove the pen from your skin until you hear the second loud click.

Q. How can I tell if my injection is complete?

A. After you press the blue injection button, you will hear 2 loud clicks. The second loud click tells you that your injection is complete. You will also see the grey plunger at the top of the clear base.

Read the full package leaflet for Omvoh inside this box to learn more about your medicine.

Last revised in